Author: acn

業績摘要：- 截至2025年6月30日止六個月(「回顧期」)的收益約為18.3億港元，較去年同期增加約7.8%。收益增加主要由於本集團持續的自然增長(主要在歐洲及澳洲地區)，並藉著我們於2025年1月完成收購泰國最大的牙科實驗室Hexa Ceram Company Limited(「Hexa Ceram」)而加快。- 截至2025年6月30日止六個月的毛利率約為54.8%；毛利約為10.1億港元，較去年同期增加約10.0%。- 本集團於截至2025年6月30日止六個月的EBITDA約為4.6億港元，較去年同期增加約21.6%。- 本集團截至2025年6月30日止六個月的純利約為2.9億港元，較去年同期增加約34.7%。- 截至2025年6月30日止六個月的每股基本盈利為30.37港仙。- 董事會已宣派截至2025年6月30日止六個月的中期股息每股普通股10.7港仙。- 截至2025年6月30日止六個月，本集團於中國內地、泰國及越南生產設施生產之數碼化解決方案個案(海外及國內)增加至約457,653件，較2024年同期增加24.4%，原因為客戶持續採用口腔內部掃描儀。香港，2025年8月29日 - (亞太商訊 via SeaPRwire.com) – 8月28日， 全球領先之義齒器材供應商-現代牙科集團有限公司（簡稱「現代牙科」或「本集團」，股份代號：03600.HK）欣然公佈截至2025年6月30日止6個月之未經審核中期業績。截至2025年6月30日止六個月，在牙科行業數碼化趨勢的持續支持下，本集團的多維度策略及持續提升的營運效率及生產力使其於本期間的收益、純利及EBITDA均創下紀錄。此情況在宏觀經濟環境充滿挑戰之時，包括牙科手術的需求普遍疲弱及貿易戰的不確定性下仍能體現。本集團充分善用位於泰國、越南及中國內地的全球化生產設施，積極應對前所未有的國際貿易環境。全球數碼化趨勢持續推動整合義齒行業，讓本集團進一步增加其於業內的市場份額。而我們數碼化的持續轉型有望改善顧客及患者的體驗，可令本集團在競爭對手中脫穎而出，表現優於同行。憑藉銷售及經銷網絡的優勢，我們於歐洲、北美、大中華、澳洲及其他國家的義齒行業均取得領先地位。歐洲市場業務自歐洲市場的銷售收益佔我們於回顧期間收益的最大部分。於回顧期間，歐洲市場錄得收益約9.2億港元，較截至2024年6月30日止六個月增加約9,734.1萬港元。此地理市場佔本集團收益總額約50.2%。歐洲市場收益增加是由於推出新產品(例如數碼化義齒)及我們最先進的數碼化流程，推動銷售訂單量增加。本集團已成為提供全面數碼化解決方案的先驅，範圍涵蓋多項微創及美容義齒解決方案以至口腔內部掃描儀及透明矯正器，本集團已準備好把握牙科行業數碼化趨勢加速帶來的機遇。本集團繼續透過建立以教育及數碼化為重點且貼近客戶需求的牙科解決方案生態系統，積極從國際及本地競爭對手取得市場份額；並透過不同的境內及境外資源有效地滿足我們客戶的高期望。本集團一直致力並將繼續裝備好自己，為市場上的牙科領域提供最先進的數碼化解決方案。北美市場業務自北美市場的銷售收益佔回顧期間收益的第二大部分。於回顧期間，北美市場錄得收益約3.7億港元，較截至2024年6月30日止六個月減少約1,964.5萬港元。此地理市場佔本集團收益總額約19.9%。雖然2025年上半年對主動美容治療的需求仍然疲弱，我們的中央化數碼流程及廣泛的生產網絡讓我們為北美客戶提供更高服務質素及營運效率。我們位於美國、中國、越南及泰國等地的多元化供應基地，在應對美國關稅的不確定性時帶來更大的彈性 - 使我們比其他競爭對手更具優勢。雖然進口產品線的數碼化起初帶動整體市場個案的增長，然而2025年4月在美國實施的關稅帶來新的不確定性及為我們以進口為主的業務單位的後續銷售帶來下跌。大中華市場業務於回顧期間，大中華市場錄得收益約2.9億港元，較截至2024年6月30日止六個月減少約4,257.6萬港元。此地理市場佔本集團收益總額約16.0%。中國內地市場面對帶量採購政策及持續價格競爭的逆境。此亦導致中國內地診所積極於香港推廣種植牙治療(香港患者就診人數明顯減少)。本集團有意轉移低利潤業務，並專注於服務中及高價值客戶，確保本集團業務能夠長期及可持續獲利。本集團對此市場的中長期前景感到樂觀，特別是在政府最新的採購相關措施中，預計(i)規範義齒價格及建立價格透明度，促進公平競爭；(ii)讓本集團領先的品牌名稱及聲望成為客戶及顧客的主要考量；及(iii)讓本集團從其規模化的生產團隊中得益及根據顧客或客戶更有效分配資源。澳洲市場業務於回顧期間，澳洲市場錄得收益約1.4億港元，較截至2024年6月30日止六個月增加約995.6萬港元。此地理市場佔本集團收益總額約7.5%。澳洲的收益錄得雙位數增長，反映牙科行業數化碼趨勢帶動更多新的數碼化產品，以及收購Digital Sleep的收益貢獻，但部分被相較於截至2024年6月30日止六個月，澳元兌港元貶值4.0%抵銷所致。其他市場其他市場主要包括印度洋國家、馬來西亞、台灣、新加坡及泰國。截至2025年6月30日止六個月，該等市場錄得收益約1.2億港元，較截至2024年6月30日止六個月增加約8,790.7萬港元。此地理市場佔本集團收益總額約6.4%。其他市場的收益增加主要由於新收購的Hexa Ceram的收益貢獻所致。展望及策略全球宏觀經濟環境仍然不明朗，地緣政治挑戰讓全球各行業處於逆境當中。然而，本集團的業務遍及全球多個地區及市場，多元化的經營使其在面對該等挑戰時享有獨特優勢。有別於在單一國家或有限地區經營的競爭對手，本集團均衡多元的國家風險策略，確保其在動盪時刻仍然堅毅不屈，平穩過渡。憑藉全球佈局及我們適應當地市場環境的能力，使本集團的表現優於競爭對手，並能把握新興機遇。數碼化勢不可擋，帶動義齒行業的整合。本集團於此趨勢中盡享優勢，憑藉其中央化數碼工作流程、先進的生產能力及全球化網絡，旨在提升營運效率及提供卓越的客戶體驗。我們持續對數碼化的投資不僅加強我們的競爭優勢，亦加快行業的整合，本集團可以從中獲得更大的市場份額。我們在過往多年作出多項標誌性收購，包括最近於2025年1月收購泰國最大牙科實驗室Hexa Ceram，本集團的全球分銷及銷售網絡進一步多元化，加強在東南亞地區的影響力。是次擴張連同我們位於美國、中國、越南及泰國等地的多元化供應基地，讓本集團在應對與貿易不明朗因素及其他地緣政治風險等相關的挑戰時帶來更高彈性。憑藉董事會豐富的經驗及克服短期挑戰的決心，本集團已準備就緒，繼續全力把握新商機，同時保持審慎及謹慎的態度，以保障股東利益。關於現代牙科集團現代牙科集團有限公司 (股份代號: 03600.HK) 為全球領先的義齒器材供應商、經銷商和顧問，專注於發展迅速的義齒行業為客戶提供定制式義齒。我們的產品組合大致可分為三類﹕固定義齒器材，例如牙冠及牙橋；活動義齒器材，例如活動義齒；及其他器材，例如正畸類器材、透明牙套、運動防護器及防鼾器。現代牙科集團擁有多個備受稱許的全球品牌，包括西歐的Labocast、Permadental及Elysee Dental、中國的洋紫荊牙科器材、香港的現代牙科器材、美國的Modern Dental USA及MicroDental、澳洲及紐西蘭的Modern Dental Pacific、新加坡的Modern Dental SG、臺灣的 Modern Dental TW、馬來西亞的 Apex Digital Dental及泰國的Hexa Ceram等。我們提供穩定和優質的產品及卓越的客戶服務，令這些公司品牌能茁壯成長。我們於全球超過 28個國家擁有超過 80 家服務中心及服務逾 30,000 名客戶。 Copyright 2025 亞太商訊 via SeaPRwire.com.

2025年中期業績表現要點：- 強勁增長：收入總額為港幣20.68億元，較去年同期大幅增長；- 扭虧為盈：報告期內，公司盈利港幣6.50億元，其中歸屬于本公司股東之盈利為港幣3.99億元，實現扭虧為盈；- 募資提升：旗下基金資產管理總規模（AUM）約港幣1,194億元，期內新增募資約港幣27.41億元；- 退出良好：基金及自有資金層面合計退出金額港幣20.18億元，退出回報倍數（MOIC）約2.78倍；- 控本增效：強化精益管理，經營成本同比下降10%，財務費用同比下降38%；- 流動性充裕：擁有現金及現金等價物約港幣81億元；- 穩健派息：中期股息為每股港幣0.05元。香港，2025年8月29日 - (亞太商訊 via SeaPRwire.com) - 中國光大控股有限公司（「光大控股」，股份代號：165.HK）公佈截至2025年6月30日止6個月（「報告期」）之中期業績。2025年上半年，中國私募股權行業逐步邁入更加穩健的發展階段。光大控股充分發揮耐心資本優勢，保持戰略定力，準確把握市場機遇，及時調整募投管退策略，夯實核心主業，價值潛能逐步釋放，公司整體經營質效大幅改善，業績強勁復蘇。報告期內，光大控股實現收入總額為港幣20.68億元，較去年同期大幅增長港幣21.82億元，主要得益於投資收入的大幅增加，充分展現了公司良好的投資眼光和長期投資底蘊。公司盈利港幣6.50億元，其中歸屬于本公司股東之盈利為港幣3.99億元，較去年同期淨虧損港幣12.82億元成功實現扭虧為盈，業績顯著改善。與此同時，公司繼續強化精細管理，保持健康穩健的經營發展。期內，經營成本同比下降10%，主動壓減槓桿，計息負債比率對比2024年末減少2%，控本增效成果顯著，財務費用同比下降38%。公司流動性保持充裕，截至2025年6月底，擁有現金及現金等價物約港幣81億元。公司資源和業務重心繼續向優勢產品聚焦，進一步穩固核心主業。報告期內，新增募資約港幣27.41億元，旗下基金資產管理總規模（AUM）約港幣1,194億元，在管基金產品72只，涵蓋一級市場基金、二級市場基金和母基金。期內，共計對9個項目進行投資，完全/部分退出項目46個。秉承與股東分享經營成果的發展理念，董事會宣派2025年中期股息為每股港幣0.05元（2024年中期股息：每股港幣0.05元）。2025年上半年經營要點一、發揮集團化運營優勢，加強募資協同體系2025年上半年，公司新完成設立淮安洪澤光啟基金和廈門海洋高新產業發展基金，總規模為人民幣25億元。淮安基金關注成長階段的新能源、新材料和智能製造等項目，上半年已完成首期實繳到位；廈門海洋基金關注海洋科技成果孵化轉化，助力海洋經濟高質量發展。同時，多只基金已完成立項，目前正按照既定規劃有序推進中。二、穩固核心主營業務，驅動業績強勁復甦報告期內，公司基金及自有資金層面合計退出金額港幣20.18億元，完成小鵬汽車、大普通信、Taboola三筆完全退出，部分退出了軟通動力、德康農牧、第四範式等多個項目，退出回報倍數（MOIC）約2.78倍，全面帶動多只基金DPI提升，為基金LP帶來了可觀收益。Circle、德康農牧、網易雲音樂等已上市項目在上半年均有良好的市場表現，為公司貢獻較好的投資收益。二級市場基金上半年精准把握結構性機會，投資業績表現較好，其中光大可轉債機會基金榮獲巴克萊評選的同類基金業績排名的第二名。三、錨定科技創新戰略，佈局重點行業領域公司基於深刻的產業洞察和前瞻性的戰略視野，在上半年加快投資節奏，重點聚焦人工智慧、芯片半導體、生物醫藥等戰略性新興產業，基金層面合計投資約港幣2.64億元。培育並支持多家科技領軍企業，包括長江存儲和武漢新芯（國產存儲芯片巨頭）、恒翼生物（腫瘤及自免創新藥研發企業）、鈞嵌傳感（國產工業自動化模組及新能源車核心感測器戰略供應商）、鈦動科技（大數據與BI領域服務商）等，支援中國科創企業做優做強。同時通過母基金支持金鎰資本、鐘鼎資本等優秀的子基金，發揮母基金資源放大、風險分散、收益多元的優勢。四、優化經營管理，釋放發展新動能公司持續優化融資結構，上半年把握國內降息週期，發行人民幣30億元的2025年第一期中期票據，年利率2.09%，創公司歷史債券發行票面利率新低。報告期內，公司整體融資成本同比下降 133個基點至 3.14%，財務費用同比下降 38%，經營成本同比下降10%，降本增效成果顯著。公司持續優化風險管理體系，通過推進風險資產分級分類、強化動態估值管理及構建風險監測預警機制，實現全流程風險防控效能提升。五、強化民生服務，商業消費更新升級光大控股發揮旗下產業優勢，提升產品服務品質，以滿足居民日益增長的消費服務需求。商業消費方面，旗下光大安石已在全國9個城市成功打造18座"大融城"購物中心，管理規模約260萬平方米，創造了約3.77萬個工作崗位，2025年上半年累計服務消費者約1.21億人次，服務商戶超過4500個。報告期內，北京重點消費類基礎設施及城市更新項目「中關村ART PARK大融城」一期順利開業，有效帶動消費體驗升級，擴大內需。六、重要投資企業穩中向好，韌性強勁中飛租賃主業發展穩健，經營質量和運營效率持續提升，股東應占淨利潤同比增長。截至2025年6月30日，中飛租賃機隊規模達181架，租賃予22個國家及地區的41家航空公司。光大養老緊抓國內康養產業發展機遇，在全國49個城市擁有各類養老機構數量237個，提供養老床位3萬余張，入住率提高1.77%。特斯聯持續深化AI技術與多產業融合，驅動多行業智慧化升級，落地國產化AI應用與數智方案，並榮獲多項權威認證。七、強化構建ESG體系，推動可持續發展報告期內，公司持續推動ESG體系建設，公司MSCI（明晟）ESG評級維持為A級，並獲得香港投資者關係協會（HKIRA）頒發的「BEST ESG（S）」獎項。公司切實發揮自身所能，履行企業公民責任擔當，上半年共組織及參與各類文化和社會公益活動46次，服務人群超過萬人，高標準履行社會責任。 2025年上半年，在光大集團的堅強領導、董事會的帶領和全體員工的共同努力下，公司經營質效全面改善，發展新動能持續增強，取得來之不易的成績。隨著中國經濟的持續向好，政策支持力度的不斷加強，中國私募股權行業將邁入高質量發展的新征程。光大控股將緊抓市場機遇，乘勢而上，為實現"十五五"良好開局夯基固本。下半年，光大控股將繼續堅持穩中求進的工作總基調，持續做好增收控本，優化經營管理，搶抓"募投管退"等關鍵業務環節的機遇，借助跨境平台和集團綜合協同的勢能，培育長期耐心資本，做好金融「五篇大文章」，通過科學的戰略規劃、專業的投資團隊和嚴格的風險管理，持續為股東創造價值。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月29日 - (亞太商訊 via SeaPRwire.com) - 富衛集團有限公司（「富衛集團」或「富衛」）今天公布截至2025年6月30日止六個月的中期業績。- 新增業務銷售額以按年化新保費計算較2024年同期上升38% 至1,246百萬美元。新業務合約服務邊際為794百萬美元，按年增幅達34%。- 稅後營運利潤增長9%，達251百萬美元。香港特別行政區和澳門特別行政區、泰國和柬埔寨、日本以及新興市場四個地區業務分部持續為集團帶來正面貢獻。- 淨利潤達47百萬美元，錄得採用國際財務報告準則第17號以來中期業績新高。- 富衛集團進一步提升財務靈活性，於2025年7月獲國際信貸評級機構穆迪上調評級，名義保險公司財務實力評級升至A2。償付能力充足率*維持在283%，產生的基本自由盈餘淨額增至417百萬美元，增幅超過一倍，展現穩健的資本狀況。來自各地區業務分部的股息收入超過500百萬美元。- 綜合有形權益上升8% 至8,150百萬美元，集團內涵價值上升8% 至6,380百萬美元，反映富衛集團於2025年上半年為股東創造的價值。富衛其後完成首次公開招股，集資總額達3,611百萬港元（約466百萬美元），並於2025年7月7日正式在香港聯合交易所有限公司主板以股份代號1828掛牌交易。- 完成構建亞洲高資產淨值客戶服務網絡，覆蓋香港特別行政區、新加坡及百慕達三地，為全球高端保險市場客戶提供多元化資產配置、財富管理及傳承規劃。全新的FWD Private 貴賓室坐落於香港黃金商業地段，現已全面投入運作。富衛集團行政總裁兼執行董事黃清風表示：「我們非常高興首次以上市公司身份公布業績，就創出採用國際財務報告準則第17號以來的中期業績新高。新業務合約服務邊際的強勁增長，展現了我們成功在亞洲貫徹以客為先策略實現可持續盈利的能力。」黃清風補充：「我們計劃將近期首次公開招股所得款項淨額用於進一步提升資本實力及財務靈活性，包括減少整體債務，以支持業務增長及拓展客戶及渠道覆蓋滲透的機會，如深化數碼能力及策略。」在香港特別行政區及澳門特別行政區，新增業務銷售額及新業務合約服務邊際均錄得顯著增長，反映本地及中國內地訪客客群持續多元的需求，以及富衛高資產淨值客戶服務全面啟動帶來的正面影響。富衛集團持續專注於多渠道分銷模式策略，並積極推動產品創新，包括根據最新監管指引所開發的指數型萬用壽險產品，以及為合資格客戶推出的大灣區跨境醫療服務。泰國與柬埔寨的業務分部新業務指標部分受到2024 年退出泰國團體醫療保險業務新單承保的影響。泰國業務具備優越條件，能夠滿足人口老化所帶來的保障、醫療及退休產品需求。其與泰國匯商銀行之獨家銀行保險合作關係保持市場第一的地位。此外，富衛泰國的代理人與顧問在 2025 年 7 月公布的百萬圓桌排名中繼續名列第二。百萬圓桌會是一個獨立國際組織，獲公認為人壽保險及金融服務業的卓越標準。日本憑藉以個人保障為核心的產品組合錄得穩健的新業務成果。公司於7月推出日圓整付保費年金產品，是公司在日本的首個儲蓄產品，標誌著富衛進軍儲蓄與退休需求市場。新興市場分部旗下數個市場在面臨行業不利因素與經濟不確定性的情況下，仍錄得強勁的新業務銷售成長。在印尼，富衛集團持有 44% 策略性投資並與印尼人民銀行的合資企業印尼人民銀行人壽保險（ BRI Life），在銀行保險新業務銷售方面位居第一。在菲律賓與越南，公司的代理人與顧問在最新公布的百萬圓桌排名中名列第二。 截至六個月止／於12月31日或6月30日^ 百萬美元，百分比除外2025 2024增長(以固定匯率按年計算) 盈利 稅後營運利潤2512239% 淨利潤/(虧損)473無意義 合約服務邊際5,9965,17411% 增長 新增業務銷售額1,24687638% 新業務合約服務邊際79457334% 新業務價值50640421% 客戶指標 客戶投保評價 –「好」或「非常好」92%92%不適用 客戶索償權益-索償的淨推薦值6364不適用 風險與資本 產生的基本自由盈餘淨額417193115% 集團當地資本總和法覆蓋率*283% 260%不適用 價值 集團內涵價值6,3805,5698% 綜合有形權益8,1507,1628% 有形權益回報率17%15%不適用 關於富衛集團富衛集團（香港聯合交易所上市代號：1828）為泛亞洲人壽及健康保險公司，服務約3,400萬名客戶，業務遍及亞洲十個市場，包括印尼人民銀行人壽保險（BRI Life）。富衛秉持以客為先的方針及科技賦能的模式，致力為客戶帶來創新定位、簡單易明的產品和簡單的保險體驗。自2013年成立以來，富衛於部分全球發展最迅速的保險市場營運業務，專注為大眾創造保險新體驗。富衛集團在香港聯合交易所有限公司主板上市，股份代號為1828。如欲了解更多資訊，請瀏覽www.fwd.com^ 所有業績數據均截至 2025年6月30日並與2024年同期比較。合約服務邊際結餘、集團當地資本總和法覆蓋率、集團內涵價值、綜合有形權益及2024年權益回報則為2024年12月之結餘／比率和增長率。增長率按固定匯率計算。除稅後營運利潤/（虧損）（非國際財務報告準則計量指標）、淨利潤/（虧損）、合約服務邊際及綜合有形權益外，其他數據均未經審計師審核。稅後營運利潤及稅後淨利潤為公司股東應佔部分，並已扣除非控股權益。新業務銷售以年化新保費100%及整付保費10%組合計算。有形權益回報的計算方式為稅後營運利潤除以期初及期末的有形權益平均值。有形權益的計算方式為經調整後公司股東應佔權益總額，減去扣除非控股權益後的無形資產。* 根據訂明資本要求基準 Copyright 2025 亞太商訊 via SeaPRwire.com.

West Palm Beach, FL, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - U.S. Polo Assn., the official sports brand of the United States Polo Association (USPA), has agreed to a multi-year partnership as the new title sponsor of The Palm Beaches Marathon. The U.S. Polo Assn. Palm Beaches Marathon, a race owned and managed by Ken Kennerly's K2 Sports Ventures, will be held in Downtown West Palm Beach, Florida, on December 13-14, 2025.USPA MarathonThis renowned marathon event is recognized for its beautiful views of the waterfront and palm-tree-lined streets and welcomes runners from across the country and around the world to the warmth of Florida during the cold winter months. It is also a qualifier for the legendary Boston Marathon."U.S. Polo Assn. is honored to be the Title Sponsor of The Palm Beaches Marathon, an iconic event that, like our brand, is deeply rooted in this vibrant community of Palm Beach County," said J. Michael Prince, President and CEO of USPA Global, the company that oversees the global, multi-billion-dollar U.S. Polo Assn. brand. "While our sport-inspired brand has a worldwide footprint in more than 190 countries, our heart and heritage are right here in The Palm Beaches, home to USPA Global, the United States Polo Association, and the USPA National Polo Center, the most prestigious polo destination in the world."The race weekend will include the 5K and 10K at 7:30 a.m. Saturday, December 13, followed by the featured Marathon, Half Marathon, and Marathon Relay on Sunday, December 14 at 6 a.m. Early registration is now open. Cost is $130 for the Marathon and $100 for the Half Marathon. The early registration fee for the 10K is $60, and $45 for the 5K. To register for The U.S. Polo Assn. Palm Beaches Marathon, visit palmbeachmarathon.com.A Health and Fitness Expo will coincide with race packet pickup on Friday, December 12, from 12 p.m. to 6 p.m. and Saturday, December 13, from 10 a.m. to 6 p.m. at the Meyer Amphitheatre, 104 Datura St., West Palm Beach. The Expo will feature the latest in health and fitness products and services, running apparel, and upcoming race information."We are excited to add a renowned global brand like U.S. Polo Assn. as the Title Sponsor of The Palm Beaches Marathon," Kennerly said. "This is a massive deal for the future of our race and its appeal to runners throughout the world. The Palm Beaches are a globally recognized blue-chip destination, and we are looking forward to continuing to grow the race not only in our community, but also on an international level."U.S. Polo Assn. brand products include apparel for men, women, and children, as well as accessories, luggage, watches, shoes, home furnishings, and more, with distribution across 190 countries through independent retail stores, department stores, U.S. Polo Assn. brand stores and e-commerce."Partnering with The Palm Beaches Marathon allows us to celebrate athletic excellence, community spirit, health and wellness, as well as the shared passion for sport that connects us locally and around the world. From the polo fields to the streets of Palm Beach, we are inspired by the athletes who give their all, and we look forward to sharing in the energy, camaraderie, and world-class competition that make The Palm Beaches Marathon truly special," Prince added.The race will support local charities, soon to be announced.WPBF 25, the Hearst-owned ABC Affiliate, will return as the Official Broadcast Station of the race and will provide extensive pre- and post-race coverage on all on-air and digital channels, as well as produce a live broadcast on Marathon race morning."WPBF 25 is thrilled to extend our partnership for a second year in a row as the Official Broadcast Station of the U.S. Polo Assn. Palm Beaches Marathon, reaffirming our commitment to help bring such a unique and exciting event like this to our community," said President and General Manager, Caroline Taplett. "Working together with our incredible partners, Ken Kennerly and the Marathon team, we are dedicated to promoting a more connected community, supporting local businesses, and inspiring participants, locally, nationally, and internationally to join us in beautiful South Florida for this one-of-a-kind experience."About U.S. Polo Assn.U.S. Polo Assn. is the official sports brand of the United States Polo Association (USPA), the largest association of polo clubs and polo players in the United States, founded in 1890 and based at the USPA National Polo Center (NPC) in Wellington, Florida. This year, U.S. Polo Assn. celebrates 135 years of sports inspiration alongside the USPA. With a multi-billion-dollar global footprint and worldwide distribution through more than 1,100 U.S. Polo Assn. retail stores as well as thousands of additional points of distribution, U.S. Polo Assn. offers apparel, accessories, and footwear for men, women, and children in more than 190 countries worldwide. The brand sponsors major polo events around the world, including the U.S. Open Polo Championship®, held annually at NPC in The Palm Beaches, the premier polo tournament in the United States. Historic deals with ESPN in the United States, TNT and Eurosport in Europe, and Star Sports in India now broadcast several of the premier polo championships in the world, sponsored by U.S. Polo Assn., making the thrilling sport accessible to millions of sports fans globally for the very first time.U.S. Polo Assn. has consistently been named one of the top global sports licensors in the world alongside the NFL, PGA Tour, and Formula 1, according to License Global. In addition, the sport-inspired brand is being recognized internationally with awards for global growth. Due to its tremendous success as a global brand, U.S. Polo Assn. has been featured in Forbes, Fortune, Modern Retail, and GQ as well as on Yahoo Finance and Bloomberg, among many other noteworthy media sources around the world. For more information, visit uspoloassnglobal.com and follow @uspoloassn.About The U.S. Polo Assn. Palm Beaches MarathonThe U.S. Polo Assn. Palm Beaches Marathon is a premier winter running event held annually in West Palm Beach, which features a range of race distances designed for runners of all abilities, including a full marathon, half marathon, 10K, 5K, and a 4-person marathon relay. Highlighted by a 100% flat, USATF-certified course, the Marathon serves as a Boston Marathon qualifier. The scenic route allows runners to experience West Palm Beach's vibrant downtown as it winds along palm-lined Flagler Drive, past historic neighborhoods, and features sparkling waterfront views. The event also supports community and charity efforts. Visit palmbeachmarathon.com.Contact InformationStacey KovalskyU.S. Polo Assn.skovalsky@uspagl.com(954) 673-1331Gary FermanSpecialty Sports(954) 558-5203SOURCE: U.S. Polo Assn. Copyright 2025 ACN Newswire via SeaPRwire.com.

Financial Highlights (Unaudited)(HKD Thousand)Six months ended 30 June20252024Revenue122,775135,347Gross Profit47,27748,767Profit Attributable to Owners of the Company8,17218,510Gross Profit Margin39%36%Basic Earnings per Share (HK cents)0.581.31HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) Dynasty Fine Wines Group Limited (“Dynasty” or the “Group”) (Stock Code: 00828), a premier grape winemaker in China, today announced its unaudited interim results for the six months ended 30 June 2025.In the first half of 2025, as the Group strengthened the effort for dry white market in coastal region and the new launch of white wine and sparkling wine products, the Group’s sales revenue of white wine products maintained a good momentum. But due to the impact of macroeconomy, fluctuations in consumer market in the PRC, as well as increase in marketing and promotion expenses, the Group's revenue for the first half of 2025 decreased by 9% to approximately HKD 123 million compared to the same period in 2024. Profit attributable to owners of the Company declined by 56% to approximately HKD 8.2 million year-on-year. Basic earnings per share were approximately HK0.58 cents per share. The overall gross profit margin increased to 39% from 36% for the corresponding period in 2024, mainly due to optimisation of product mix during the period.Sales of white wines products of the Group served as the Group’s primary revenue contributor during the period. Sales revenue of red and white wines products accounted for approximately 41% and 54% of the Group’s overall revenue respectively for the period. During the period, the gross profit margin of red wine products and white wine products were 38% and 39% respectively.The Group has been actively pursuing innovation, embracing the “5+4+N” product strategy, with “N” standing for developing various customised products and continuously creating new products to meet the diverse needs of different Chinese consumer groups. During the period under review, the Group continued launching new products and carrying out product upgrade, that can better suit different palates, and cater for consumers with different spending power. That was done with an aim to invigorate the brand, as well as consolidating the image of Dynasty representative of domestic grape wine brand. The Group produced a wide range of more than 100 wine products under the “Dynasty” brand to meet the demands and preferences of different consumer groups mainly in the mass-market segments in the PRC wine market. During the period under review, the Group launched a new high-end product, i.e. Dynasty Chinese Zodiac Commemorative Dry Red Wine for the Yi Si Year of Snake, integrating with the Chinese zodiac culture and the leading rise of Chinese style fashionable products, by presenting the zodiac culture in a youthful visual language to attract potential consumers. During this period, the Group continued strengthening cooperation with the Wine Association and carried out activities such as "Dragon University Tours" to further expand the brand's awareness and reputation among young people. Based on its existing high-quality products, the Group continues to introduce new products and promote product upgrades. The Group participated in the 112th China Food & Drinks Fair in March 2025, introducing new products such as Tianyang Tea-flavoured wine series, Dynasty Baifu VSOP brandy, etc., to further improve its product matrix and provide consumers with diverse consumption choices. Breaking through from the constraints of traditional wine, this tea-flavoured wine series, with its core concept of "tea and wine fusion", has captured market attention with its unique craftsmanship. Based on white wine, this Tea-flavoured wine infuses the aromas of jasmine and Pu'er tea, creating a new oriental flavour within the traditional sparkling wine landscape. During the China Food & Drinks Fair, the Group also held wine-tasting events, where the new wines from Dynasty Tianxia Winery won industry praise for their unique flavor and exquisite craftsmanship.Further to our commitment to core wine business in the PRC, the Group will develop new alcoholic beverages segments such as sauce-flavour baijiu, yellow wine and special yellow wine – Chenpi wine, through the newly set up joint venture companies, so as to diversify the sources of revenue. Dynasty sauce-flavour baijiu products, namely ‘Han’, ‘Tang’, ‘Song’ and ‘Ming’ have been newly launched in Tianjin core-market with enthusiastic responses and will be further strategically promoted to other regions in the second half of the year. The sauce-flavour baijiu products satisfy the needs of customer groups with different spending habits and contributing to the Group’s business. In the future, the continuous development and expansion of the sauce-flavour baijiu industry and the improvement of the level of customer groups will inevitably and effectively drive the increase in the sales of Dynasty wine and related products, thereby enhancing our industry influence and brand awareness. For the yellow wine project, after planning, a manufacturing plant with a tank capacity of 3,000 tonnes of yellow wine and special yellow wine – Chenpi wine in Jiangsu will be under construction in the second half of 2025. Upon completion of the construction works, the Group will be able to produce special yellow wine – Dongtai Chenpi Wine which allows the Group to effectively expand product categories, seize development opportunities in the Chinese yellow wine industry, and achieve a major strategic move towards high-quality development of the wine industry.Regarding E-commerce sales, the e-commerce team of the Group comprehensively operated online stores on traditional e-commerce platforms, such as JD.com, Tmall and Pinduoduo for product sales, as well as comprehensive innovation on its brand, product categories, and business systems, procedures and models via interest-based ecommerce platforms, including RED, Kuai and TikTok during the period under review. The Group’s autonomous brand communications could continue to gain the attention of mainstream consumer groups and demographic segments, and enhance effective market penetration of the Group’s products targeted at young consumers. The e-commerce team also actively cultivate e-commerce live broadcasting talents to further expand its sales channels so as to build up a new customer base.In addition, during the period under review, the Group had boasted brilliant results in major wine appraisal competitions. Among the numerous awards, “Dynasty Jin. Y Brandy XO barrel-aged 12 years” has won the Silver Award, at the 2025 International Wine & Spirit Competition (“IWSC”). The competition is considered the international standard for wine and spirits quality. Dynasty Baifu VSOP Brandy, Golden Dynasty Marselan Dry Red Wine, as well as Tianyang Tea-flavoured Wine series are also awarded at the “2024 Qingzhuo Awards” in respective categories by China Alcoholic Beverages Association. “Dynasty Mengyuan White wine” has also won the Grand Gold Medal at the France International Wine Awards (“FIWA”) China region, Spring 2025 for its excellent quality. In addition, “Dynasty Inherit series -Dry Red Wine” has garnered the Gold Award at the same competition. These wines stood out from other entries for their elegant aroma, smooth body and round taste, and won the awards at the competitions, showing the charm and strengths of Dynasty wines to the country and the world.Mr. Wan Shoupeng, Chairman of Dynasty, concluded, “Looking ahead to the second half of 2025, the Group will continue to focus on market and consumer demand and promote product quality through technological innovation. At the same time, the Group will continue to innovate marketing strategies to stimulate brand vitality, further expand the market share of Dynasty’s products, strengthen Dynasty’s brand image representative of domestic wines, and set a benchmark for the Chinese wine industry, with the aim of bringing Dynasty’s superior wines to more consumers in the PRC. The Group will continue to proactively develop new marketing prospects through innovation in product categories and consumption scenarios, and cross-industry co-operations in order to boost sales volume, which is in line with the country’s effort to promote domestic consumption and release the consumption growth potential.”About Dynasty Fine Wines Group LimitedDynasty Fine Wines Group Limited was listed on the Main Board of The Stock Exchange of Hong Kong Limited with the stock code 00828 on 26 January 2005. Founded in 1980, Dynasty is the premier grape winemaker in China. It is principally engaged in the production and sale of grape wine products under its reputable “Dynasty” brand. Dynasty is the first Sino-foreign joint venture wine company in China with Tianjin Food Group Limited and the French grape wine giant, Remy Cointreau, as its current major shareholders. The Group produces and sells more than 100 grape wine product series, and introduces imported wine products, providing high-quality and value-for-money grape wines to the full range of consumer groups in China. Copyright 2025 ACN Newswire via SeaPRwire.com.

Healthy pipeline, diversification and cost discipline position the Company for long-term growthKey Financial Performance Highlights for the Financial Year (FY2025):- Group’s total revenue for the financial year is RM222.7 million, mainly driven by the e-mobility and energy storage segment, supplemented by the electronics segment.- Recorded LAT of RM40.9 million for Q4FY2025 and LAT of RM27.2 million for the financial year.BANGI, Malaysia, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Technology leader in providing turnkey, intelligent manufacturing automation solutions, Genetec Technology Berhad (“Genetec” or the “Company”), today announced its financial results for the year ended 30 June 2025 (“FY2025”). The Company reported a gross profit of RM12.7 million for FY2025, supported by continued deliveries in the e-mobility and energy storage segments. The Company recorded a loss after tax (LAT), mainly reflecting higher logistics costs and non-operational, one-off expenses, while underlying fundamentals remain intact.Performance was affected by logistics constrains and one-off costs. Despite this, the Company continued to invest in strengthening its capabilities and supporting future project scopes. Profitability is expected to normalise in FY2026 as markets stabilise and as projects are executed effectively. Genetec is also reinforcing its organisation by bringing in experienced professionals into strategic roles, aimed at broadening capabilities and supporting its long-term diversification strategy.Healthy Orderbook through Diversified MarketsThe Company’s order and tender books remain intact and healthy, underpinned by recurring orders from existing clients as well as new opportunities from a more diversified client base across multiple industries and regions.Deepening Engagement with Existing ClientsAlongside diversification, Genetec continues to strengthen partnerships with its existing clients. Recurring orders and new programme awards reflect the trust and confidence these clients place in Genetec’s execution capabilities and proven track record.Global Manufacturing Trends Creating TailwindsGlobal geopolitical shifts are leading manufacturers across industries to re-evaluate their production footprints and enhance operational resilience. This trend is fuelling greater demand for automation solutions that are flexible, cost-competitive, and consistently high in quality. With its Malaysia-based production model, strong international track record, deep technical know-how, and agile manufacturing capabilities, Genetec is well-positioned to support clients as they navigate and adapt to these evolving requirements.Positive Outlook for BESS PipelinesThe Battery Energy Storage System (BESS) segment continues to gain momentum, with Genetec executing projects across domestic and international markets, and seeing growing local interest in BESS solutions for peak shaving following the recent tariff revision.Chief Executive Officer and Co-founder of Genetec, Chin Kem Weng commented, “FY2025 was a year of investment and transition. We made deliberate strategic choices to strengthen our foundation, safeguard delivery timelines, and support new project scopes. While these factors impacted margins in the short term, they reinforce our capabilities and credibility as a trusted partner. We expect profitability to normalise as market stabilise and as we build on execution experience.”“At the same time, our pipelines remain healthy, supported by recurring orders from existing clients and new opportunities across diversified industries and regions. Our inclusion in both the conventional and Shariah FTSE4Good Bursa Malaysia indices reflects the strength of our governance and sustainability practices. As Genetec approaches our 30th year in business, we remain committed to creating long-term value for clients, shareholders, and stakeholders.”About Genetec Technology BerhadGenetec Technology Berhad is a public listed company on the Main Market of Bursa Malaysia Securities Berhad (Stock code: 0104) and a global leader in providing customised, turnkey smart factory automation solutions. With a strong international footprint, it serves a diverse range of industries including electric vehicle (EV), e-mobility and energy storage, automotive, hard disk drives (HDD), consumer electronics, appliances, and pharmaceuticals.For more information please visit: https://genetec.net/.Issued on behalf of Genetec Technology Berhad by Narro CommunicationsFor media enquiries on Genetec Technology Berhad, please contact:Farah Shahrul Narro Communications E: farah@narrocomms.com Joyce ShaminiNarro CommunicationsE: joyce@narrocomms.com Copyright 2025 ACN Newswire via SeaPRwire.com.

SHANGHAI, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Hua Medicine (the “Company”, HKEx: 2552) announced the unaudited consolidated results of the Company and its subsidiaries for the six months ended June 30, 2025 (the “Reporting Period”), as well as the Company's business progress during the first half of the year and future outlook. During the Reporting Period, the commercialization of the Company's core product, HuaTangNing (dorzagliatin tablets), accelerated. The Company’s independent operational capabilities improved significantly. R&D progress advanced smoothly and the Company’s financial performance achieved breakthrough growth, laying a solid foundation for long-term sustainable development.Sales of HuaTangNing increased by 108% year-on-year, with net sales increasing by 112% year-on-year. Reimbursement coverage continued to expand, with a significant increase in prescription volumes across Tier 2 and Tier 3 hospitals, as our comprehensive commercialization strategy achieved significant results.Following the termination of the exclusive promotion service agreement with Bayer, the Company recognized a one-time release of previously deferred income of RMB 1,243.5 million, achieving a profit of RMB 1,183.9 million for the first half of the year. This is the Company's first profit during the performance period.A real-world study (BLOOM) involving 80 centers and 2,000 patients with Type 2 diabetes conducted in China further demonstrated the broad applicability and safety of dorzagliatin.A registration application has been submitted in Hong Kong for Dorzagliatin 75mg (brand name: MYHOMSIS®), aiming to extend its presence across Greater China and Southeast Asia.Gross profit margin improved significantly, as production scale and operational efficiency continued to be optimized.“The first half of 2025 was a critical stage in Hua Medicine’s transformation and development. Following the full takeover of the commercialization of HuaTangNing, the Company achieved double-digit growth in sales and revenue through its independently established sales team, thereby validating the effectiveness of the new business model. We have also submitted a new drug application in Hong Kong, China, laying the foundation for dorzagliatin to expand from China to Southeast Asia and the global market,” said Dr. Li Chen, founder and CEO of Hua Medicin “Dorzagliatin has continued to demonstrate broad therapeutic potential in real-world studies, and new evidence has been found in basic research regarding diabetes remission, cognitive improvement, lipid improvement, and muscle gain, further consolidating Hua Medicine’s global leadership in GKA research and development and treatment. In the future, Hua Medicine will continue to focus on diabetes and the entire field of metabolic diseases, driving innovation through research and development and market expansion to bring the benefits of China's original innovative drugs to more patients worldwide.” Business Highlights and Operational ProgressCommercialization transformation achieved remarkable results, with doubling of sales and profits.Effective from January 1, 2025, the Company terminated its exclusive promotion service agreement with Bayer and fully took over the commercialization of HuaTangNing (å''å ‚å®'®) in China. During the Reporting Period, with unit prices remaining consistent with the same period in 2024, sales of HuaTangNing reached 1,764,000 packs, a year-on-year increase of 108%. Net sales reached RMB217.4 million, a year-on-year increase of 112%. Leveraging strong commercial execution and continuously improving operational efficiency, the Company is moving toward profitability. Hua Medicine has successfully transitioned to a fully independent commercialization phase, confirming growing market demand and the efficient execution capabilities of its independent sales team.Sales of HuaTangNing continued to benefit from its inclusion in China’s National Reimbursement Drug List (NRDL), which took effect in January 2024. Reimbursement coverage under the NRDL has significantly increased accessibility, especially in Tier 2 and Tier 3 hospitals, and played a critical role in accelerating patient adoption.Due to expanded production scale and improved cost efficiency, the Company's gross profit margin increased to 54.2%, higher than 46.5% in the same period last year.With sales revenue growing 112% year-on-year, the Company's sales expenses during the Reporting Period were RMB64.2 million for the six months ended June 30, 2025, growing only 5% compared to the same period last year. The composition of our selling expenses for the six months ended June 30, 2025 changed significantly from the same period in 2024 due to the Company incurring selling expenses directly as a result of assuming sole commercialization responsibilities for HuaTangNing in China, while no longer owing promotion expenses to the former commercialization partner. These figures also reflect a significant positive trend towards profitability and demonstrate our business strategy of optimizing profitability by controlling commercialization sales expenses of HuaTangNing and maximizing production efficiency, where our selling expenses in the first half of 2025 represent approximately 29.5% of total revenue whereas in the first half of 2024, our selling expenses represented approximately 59.5% of total revenue. After terminating the exclusive promotion service agreement with Bayer, the Company recognized a one-time release of previously deferred income of RMB1,243.5 million and transitioned to self-driven growth. Hua Medicine achieved a pre-tax profit of RMB 1,183.9 million for the first half of the year, marking a key milestone of Hua Medicine towards sustainable profitability.As of June 30, 2025, the cash balance was RMB1,022.8 million, laying a solid foundation for the Company's future R&D and commercialization initiatives.Clinical research continues to deepen, with new evidence supporting treatment potentialHua Medicine is conducting multiple post-marketing studies to evaluate the long-term safety and effectiveness of dorzagliatin across diverse patient populations, both in monotherapy as well as in combination with other popular approved anti-diabetic drugs, such as GLP-1 receptor agonists, insulin, DPP-IV inhibitors and SGLT-2 inhibitors. These studies are generating new clinical insights into glucose control, cognitive outcomes, and potential for diabetes remission.A real-world study (BLOOM) is being conducted in 2,000 patients with Type 2 diabetes across 80 centers in China. BLOOM has already completed one-year follow-up in over 1,000 participants. In the real-world setting, BLOOM further demonstrates the broad applicability and safety of dorzagliatin. Patients receiving dorzagliatin in routine clinical practice present with a heterogeneous mix of comorbidities, including various cardiovascular and renal disorders and are managed with multiple concomitant medications. In addition to metformin, more than 60% of patients concurrently used SGLT-2 inhibitors, insulin, GLP-1 receptor agonists, or DPP-IV inhibitors and other anti-diabetic drugs with dorzagliatin. In monotherapy or in combination with the popular above-mentioned anti-diabetic drugs, dorzagliatin was generally well tolerated, and its safety profile remained consistent with previously established data.Hua Medicine presented new data at the 2025 American Diabetes Association (ADA) conference, reinforcing dorzagliatin’s potential as a disease-modifying therapy. Insights into the novel mechanism of action (MOA) of dorzagliatin as a therapeutic GKA were published in Diabetes.Research and Development Pipeline and Future OutlookThe company filed its application for registration of dorzagliatin 75mg in Hong Kong as MYHOMSIS®, aiming to extend its presence across Greater China and southeast Asia.We are continuing expansion on our product pipeline through development of fixed dose combination of metformin and dorzagliatin for patients who have failed to control blood glucose levels while using high dose metformin (daily dose>1500 mg). In the loose dose combination study-DAWN Trial, dorzagliatin add-on to metformin provided HbA1c reduction of greater than 1% and post meal glucose reduction of greater than 5 mmol/L. These desirable glycemic control levels coupled with a very safe 0.8% hypoglycemic rate would suggest strong potential demand for a branded oral anti-diabetic medication using a convenient fixed dose combination of dorzagliatin and metformin. The Pre-IND submission has been achieved in August 2025, and we are expected to initiate the bioequivalence study in early 2026.We are also advancing the combination of dorzagliatin with GLP-1RA, SGLT-2 inhibitors, insulin and DPP-IV inhibitors through combined effects in collecting real world evidence and proof of concept studies in animal models. The synergy between dorzagliatin with these agents has the potential to expand our indications into other diseases in metabolic disorders, such as obesity and MASH.We continue to enhance our collaborations with leading international research institutions. A Phase I investigator-initiated trial supported by the Group and conducted at the University of Pennsylvania – designed to evaluate the efficacy and safety of dorzagliatin in patients with cystic fibrosis-related diabetes (CFRD) – has received clearance from the U.S. FDA.We will continue our engagement in diabetes prevention, opportunities in metabolic disorder related neurodegeneration disease and eventually find a new way to increase healthy life span and longevity in humans.We continue to invest in digital technology platforms to create synergies across functions and enhance branding opportunities using AI technology.As illustrated in our product pipeline chart, we will continue to advance our R&D efforts for both dorzagliatin and our 2nd generation GKA on our own as well as in collaboration with academic and strategic partners. We are working on the registration of dorzagliatin in Hong Kong and continue to seek partnerships in Southeast Asia and Belt and Road nations. In addition, we will continue our business development efforts on our 2nd generation GKA for the global markets based on the initial success of the Phase 1 single-ascending dose study in the United States and the initiation of our Phase 1 multiple ascending dose study planned for late 2025 or early 2026.Financial SummaryAs of June 30, 2025- Bank balances and cash amounted to approximately RMB 1,022.8 million.- Total revenue was approximately RMB217.4 million, representing a year-on-year increase of 112%. Sales of HuaTangNing (å''å ‚å®'®) reached 1,764,000 packs, representing a year-on-year increase of 108%.- Total gross profit was approximately RMB117.8 million, representing a year-on-year increase of 147%. Gross margin was approximately 54.2%, increased by approximately 7.7 percentage points, as compared with the six months ended June 30, 2024.- Total other income amounted to approximately RMB1,254.6 million , of which Bayer's one-time release of previously deferred income was RMB1,243,5 million.- Total expenditures were approximately RMB187.1 million, of which research and development expenditure was approximately RMB65.8 million.- Profit before tax was approximately RMB1,183.9 million, representing approximately 932% for the six months ended June 30, 2025Forward-Looking StatementsThis document contains statements regarding Hua Medicine’s future expectations, plans, and prospects for the Company and its products. These forward-looking statements pertain only to events or information as of the date they are made and may change due to future developments. Unless required by law, we are not obligated to update or publicly revise any forward-looking statements or unexpected events after the date of such statements, regardless of new information, future events, or other circumstances. Please read this document carefully and understand that our actual future performance or results may differ materially from expectations due to various risks, uncertainties, or other legal requirements.About Hua MedicineHua Medicine (The “Company”) is an innovative drug development and commercialization company based in Shanghai, China, with companies in the United States and Hong Kong. Hua Medicine focuses on developing novel therapies for patients with unmet medical needs worldwide. Based on global resources, Hua Medicine teams up with global high-calibre people to develop breakthrough technologies and products, which contribute to innovation in diabetes care. Hua Medicine's cornerstone product HuaTangNing (dorzagliatin tablets), targets the glucose sensor glucokinase, restores glucose sensitivity in T2D patients, and stabilizes imbalances in blood glucose levels in patients. HuaTangNing was approved by the National Medical Products Administration (NMPA) of China on September 30th, 2022. It can be used alone or in combination with metformin for adult T2D patients. For patients with chronic kidney disease (CKD), no dose adjustment is required. It is an oral hypoglycemic drug that can be used for patients with Type 2 diabetes with renal function impairment.For more informationHua MedicineWebsite: www.huamedicine.comInvestors E-mail: ir@huamedicine.comMedia E-mail: pr@huamedicine.comPress DisclaimerFor accuracy and completeness in context, information related to products marketed in China in this material, especially those identified or required, should comply with documents approved by Chinese regulatory authorities.Additionally, such information should not be interpreted as a recommendation or promotion of any drug or treatment, nor should it replace medical advice from healthcare professionals. For medical-related matters, please consult a healthcare professional. Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 28, 2025 - (ACN Newswire via SeaPRwire.com) - Shoucheng Holdings Limited (0697.HK, hereinafter referred to as “Shoucheng Holdings”), Beijing Shoucheng Robotics Technology Industry Co., Ltd. (hereinafter referred to as “Shoucheng Robotics”), IAT Automobile Technology Co., Ltd. (300825.SZ, hereinafter referred to as “IAT”), and Beijing IATROBOT Technology Co., Ltd. (hereinafter referred to as “IATROBOT”) officially signed a strategic cooperation framework agreement.The four parties will leverage their respective strengths to carry out comprehensive cooperation in technological innovation, application deployment, industry chain collaboration, and talent cultivation within the robotics sector, jointly accelerating the development of new business models in the “Robotics + Automobiles” field.I. Industry Background: Robotics Entering the Acceleration Phase of Application DeploymentAt present, the global robotics industry is in a stage of rapid development, with national strategies and policies being introduced intensively. On August 26, the State Council officially released the Opinions of the State Council on Deeply Implementing the “AI+” Initiative (Guo Fa [2025] No. 11), which explicitly calls for promoting the extensive and in-depth integration of artificial intelligence with various industries and fields across the economy and society, and accelerating the formation of new models of intelligent economy and intelligent society characterized by human-machine collaboration, cross-industry integration, and co-creation.Under this national strategy, the robotics industry is shifting from “technological breakthroughs” to “application deployment.” Automobiles and robotics, as two highly complementary industries, are increasingly showing a trend of cross-sector integration. The cooperation between Shoucheng Holdings and IAT Group, under the dual drivers of favorable policy and strong market demand, will inject new momentum into robotics applications across key segments such as R&D, manufacturing, transportation, and mobility services.IAT is a leading enterprise in China’s automotive design field and the only independent automotive design company listed on the A-share market. The company provides full-process services ranging from complete vehicle R&D and design to core component manufacturing, while pursuing a globalization strategy of “technology + supply chain.” According to public information, IAT has served more than 80 clients and participated in the development of nearly 500 vehicle models. Its clients include major OEMs such as FAW, Dongfeng, BAIC, Geely, emerging EV brands, as well as joint-venture automakers. This highlights IAT’s strong OEM resources and delivery capabilities across the automotive value chain.At the same time, through its subsidiary — Beijing IATROBOT Technology Co., Ltd. — IAT has officially entered the robotics sector. IATROBOT is dedicated to building an integrated R&D, design, and simulation training platform, capable of supporting multi-scenario robotics development from simulation and testing to optimization. The company has already launched multiple R&D projects, including wheeled robots, underwater robots, drilling robots, and pet-care robots, demonstrating its potential in cross-scenario development and industry collaboration. The involvement of IATROBOT expands the scope of this cooperation beyond traditional automotive design, providing important support for the integration of robotics R&D, simulation, and automotive industrialization.By partnering with IAT and IATROBOT, Shoucheng will be able to embed robotics technologies deeply into the core stages of the automotive value chain, such as vehicle manufacturing, intelligent assembly, and production line testing. This will enable robots to truly enter the production line and accelerate industrial adoption. This strategic cooperation is not merely a technological connection — it leverages IAT’s extensive OEM client network to move robotics scenarios from “next-door demonstrations” directly into the “factory workshop,” bridging the crucial pathway between R&D validation and scaled industrial delivery.II. Key Areas of Cooperation: Balancing R&D Breakthroughs and Application DeploymentGuided by the State Council’s “AI+” Initiative, the four parties will anchor their collaboration on the full chain of “technology R&D — industrial application — ecosystem co-construction,” working together to drive industrial innovation. The cooperation will focus on the following areas to promote the deep integration of robotics and automobiles:(1) Technological Innovation and Joint R&DThe four parties will jointly build an integrated robotics R&D and simulation platform, drawing on the comprehensive R&D system of the automotive industry. The focus will be on achieving breakthroughs in key areas such as motion control, structural optimization, automotive-grade components, and large-scale manufacturing. Leveraging NVIDIA Isaac/Omniverse technology, the parties will co-develop an integrated simulation training platform that not only supports simulation of robotics applications in automotive R&D, manufacturing, and testing, but also enables cross-scenario simulations such as collaborative operations between autonomous driving vehicles and logistics robots.In addition, a mechanism for data and outcome sharing will be established: Shoucheng Holdings will provide operational data resources from transportation and mobility scenarios, while IAT will contribute expertise in automotive engineering and robotics R&D, together forming a complete closed loop spanning simulation — R&D — validation — production line application.(2) Priority Procurement and Synergy MechanismAcross R&D design, simulation training, complete machine and component supply, the four parties will adopt a priority procurement mechanism, under which signatories will be given preference as partners under equivalent conditions. Shoucheng Holdings and Shoucheng Robotics will focus on product promotion, distribution, and supporting services, while IAT and IATROBOT will concentrate on technology R&D, engineering validation, and customized whole-machine development.The parties will also work together to advance secondary development of robotic systems, ensuring optimal adaptation of robotics products to scenarios such as automotive production lines, intelligent assembly, and line testing. Through division of labor and collaborative mechanisms, a complementary cycle of product supply — technological innovation — application feedback will be established, accelerating the conversion of results and enhancing commercialization efficiency.(3) Talent DevelopmentLeveraging the research and industrial platforms of Shoucheng, IAT, and their partners, the four parties will jointly carry out technological problem-solving, simulation training, and application pilots, providing researchers and engineers with cross-industry, cross-scenario practical environments. Regular technical seminars and industry forums will be held, inviting experts and upstream and downstream enterprises to participate, thereby establishing a joint talent development mechanism. This initiative aims to cultivate a new generation of young researchers with both automotive engineering backgrounds and practical experience in robotics industrialization, laying a solid talent foundation for long-term growth.(4) Expanding Development HorizonsThe four parties will closely align with national strategies for “AI+” and robotics industry development, with a focus on scaling up “Robotics + Automobiles” applications in R&D, manufacturing, testing, and mobility services. Building on this foundation, the cooperation will gradually extend into broader fields such as smart transportation, intelligent manufacturing, healthcare, education, and public services, covering the design, R&D, production, testing, and commercialization of robots and core components. At the same time, by integrating capital and industry, the parties will drive coordinated upgrades across the value chain, ultimately forming a full-cycle closed loop from R&D validation to large-scale application. This will create a demonstrative “Robotics + Automobiles” application matrix, achieving mutual benefits and long-term value creation.III. Strategic Significance: Establishing a New Benchmark for Robotics ApplicationsThe greatest value of the robotics industry lies in real-world applications, and “Robotics + Automobiles” stands out as one of the most promising and high-potential application directions. From complete vehicle R&D to intelligent manufacturing, from traffic scheduling to smart mobility, robots will create tremendous value across the entire automotive value chain.Shoucheng Holdings, leveraging its capital platform, ecosystem resources, and industrial fund advantages, has invested in leading domestic enterprises such as Unitree Robotics, Galbot, Noetix Robotics, Galaxea-AI, and Booster Robotics, equipping it with the capability to integrate frontier technologies. Shoucheng Robotics has established collaborations with hundreds of high-quality upstream and downstream enterprises, making it one of the most comprehensive resource-linking platforms in China. IAT and IATROBOT, in turn, bring mature automotive engineering systems into robotics R&D and industrialization. Together, the combined strengths of both sides will form a complete pathway of “R&D — iteration — application — scale-up.”By joining forces with IAT, Shoucheng will further integrate its scenario resources and industrial ecosystem with IAT’s expertise in vehicle R&D, engineering capabilities, and industrialization experience. Over the next one to two years, the cooperation will focus on the deep integration of “Robotics + Automobiles,” taking the lead in demonstrating large-scale applications across vehicle R&D, production and manufacturing, smart transportation, and mobility services. This will accelerate the transition of robotics from laboratories to industrialization and large-scale deployment, creating a demonstrative “Robotics + Automobiles” application matrix. At the same time, the cooperation will also look to the international market, bringing Chinese solutions to the global stage, fostering new quality productivity, and generating long-term value for shareholders.Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 ACN Newswire via SeaPRwire.com.

HONG KONG, Aug 29, 2025 - (ACN Newswire via SeaPRwire.com) - China Everbright Limited ("CEL" or "the Company", stock code: 165.HK) announced its Interim results for the six months ended 30 June 2025 ("the reporting period").Highlights of the 2025 Interim Results- Strong Growth: Total income reached HK$2,068 million, representing a significant increase compared with the same period last year;- Turning Around from Loss to Profit: During the reporting period, the Company recorded a profit of HK$650 million, of which the net profit attributable to shareholders of the Company was HK$399 million, successfully turning around from a net loss;- Fundraising Increase: The total assets under management (AUM) of CEL's funds amounted to approximately HK$119.4 billion, with new fundraising amounting to approximately HK$2,741 million;- Successful Exits: The total exits from funds and principal investments amounted to HK$2.018 billionï¼›with a MOIC (multiple on invested capital) of approximately 2.78 times;- Cost Control and Efficiency Enhancement: Enhanced lean management led to a 10% year-on-year decrease in operating costs and a 38% year-on-year reduction in finance costs;- Adequate Liquidity: The Company had cash and cash equivalents of approximately HK$8.1 billion;- Steady Dividend: An interim dividend of HK$0.05 per share for 2025.In the first half of 2025, China's private equity industry entered a more stable stage of development. Leveraging its strengths as patient capital, CEL maintained strategic focus, seized market opportunities with precision, and promptly adjusted its fundraising, investment, management, and exit strategies. By consolidating its core businesses, gradually unlocking value potential, and significantly improving overall operational efficiency, the Company achieved a strong rebound in performance.During the reporting period, CEL realised total income of HK$2,068 million, representing a significant increase of HK$2,182 million from the same period last year. This was mainly due to a significant increase in investment income, which fully demonstrated the Company's sound investment vision and solid foundation in long-term investing. The Company recorded a profit of HK$650 million, of which the net profit attributable to shareholders of the Company amounted to HK$399 million, successfully turning around from a net loss attributable to shareholders of HK$1,282 million in the same period last year, representing a significant improvement in performance.Meanwhile, the Company continued to strengthen its refined management, sustaining healthy and steady business development. During the reporting period, operating costs represented a year-on-year decrease of 10%, with proactive leverage reduction measures implemented. The gearing ratio decreased by 2% compared with the end of 2024, while finance costs fell 38% year-on-year, demonstrating significant results in cost control and efficiency improvement. As at the end of June 2025, the Company had cash and cash equivalents of approximately HK$8.1 billion, representing sufficient liquidity.By concentrating its resources and business focus on high-potential products, the Company further reinforced its core business. During the reporting period, with new fundraising amounting to approximately HK$2,741 million, the total AUM of CEL’s funds amounted to approximately HK$119.4 billion, managing 72 fund products and covering primary market funds, secondary market funds, and fund of funds. During the reporting period, the Company invested in a total of 9 projects and exited, fully or partially, from 46 project.Following the practice of sharing the Company's operating results with shareholders, the Board declared interim dividend of HK$0.05 per share for 2025 (2024 interim dividend: HK$0.05 per share).Business Highlights in the First Half of 2025Firstly, CEL Harnessed the Strengths of Group-Based Operations to Enhance Fundraising SynergyIn the first half of 2025, the Company successfully launched the Huaian Hongze Guangqi Fund and the Xiamen Marine High-Tech Industrial Development Fund, with a total scale of RMB2.5 billion. The Huaian Fund targets growth-stage projects in the areas of new energy, new materials, and intelligent manufacturing, with its first round of capital contribution completed in the first half of the year. The Xiamen Marine Fund is dedicated to incubating and transforming scientific and technological innovations in the marine sector, driving the high-quality development of the marine economy. At the same time, several other funds have been approved and are progressing smoothly, following the established plan.Secondly, CEL Strengthened Core Businesses to Drive Robust Recovery in PerformanceDuring the reporting period, the Company total exits from funds and principal investments amounted to HK$2.018 billion. This include the full exit from Xpeng Motors, DAPU Telecom, and Taboola, alongside partial exit from iSoftStone, Dekon Food and Agriculture, 4Paradigm, and other projects. With a MOIC (multiple on invested capital) of approximately 2.78 times, these exits significantly boosted the DPI of multiple funds, generating substantial returns for LPs. Several listed projects, including Circle, Dekon Food and Agriculture, and NetEase Cloud Music, delivered strong market performance in the first half of the year, making notable contribution to the Company's investment returns. In the first half of the year, secondary market funds expertly capitalised on structural opportunities, achieving impressive investment performance. Notably, the Everbright Convertible Bond Opportunity Fund ranked second among similar funds in Barclays' performance rankings.Thirdly, CEL Anchored Strategy Around Scientific and Technological Innovation, With a Particular Focus on Key Industry SectorsGuided by deep industrial insight and a forward-looking strategic vision, the Company accelerated its investment activity in the first half of the year. It targeted emerging strategic industries such as artificial intelligence, chips and semiconductors, and biomedicine, with a total investment of approximately HK$264 million by funds. We have nurtured and supported a number of technology leaders, including Yangtze Memory and Wuhan Xinxin (both prominent domestic memory chip producers), HengYi Biotech (a company engaged in the research and development of innovative drug for tumors and autoimmune diseases), J-Sensor (astrategic supplier of domestic industrial automation modules and core sensors for new energy vehicles), and Tec-Do (a service provider in the field of big data and BI), among others. These investments reflect our commitment to strengthening China’s science and technology enterprises. Meanwhile, CEL supported excellent sub-funds such as Jinyi Capital and Eastern Bell Capital through its FoF platforms. These FoF investments allow us to fully leverage the advantages of resource amplification, risk diversification, and diversified returns.Fourthly, CEL Optimise Business Management to Unlock Growth MomentumIn the first half of the year, the Company continued to optimise its financing structure and took full advantage of the domestic interest rate cut cycle, issuing RMB3 billion in the first tranche of its 2025 medium-term notes at a coupon rate of 2.09% per annum — the lowest coupon rate in the Company's bond issuance history. During the reporting period, the Company's overall financing cost declined by 133 basis points year-on-year to 3.14%, while its finance costs reduced by 38% year-on-year. Operating costs also recorded year-on-year decrease of 10%, underscoring the solid progress made in reducing costs and increasing efficiency. The Company continued to optimise its risk management framework. CEL advanced the classification of risk assets, reinforced dynamic valuation management, and established a risk monitoring and early warning system, thereby improving the effectiveness of risk prevention and control across the full business cycle.Fifthly, CLE Enhanced Public Services and Upgraded Commercial Consumption.CEL leveraged its industrial strengths to enhance the quality of its products and services, catering to the growing demand for consumer services among citizens. In the commercial consumption arena, EBA successfully launched 18 "IMIX Park" shopping centres across nine cities nationwide,managing approximately 2.6 million square metres in total. These centres created approximately 37,700 jobs, attracted approximately 121 million customer visits, and hosted more than 4,500 tenant merchants in the first half of 2025. During the reporting period, Phase I of the "Zhongguancun ART PARK IMIX Parks", a flagship consumption infrastructure and urban renewal project in Beijing, opened smoothly, significantly upgrading the consumer experience and giving a strong boost to domestic demand.Sixthly, Key Portfolio Companies Maintain Stable Growth with Strong ResilienceThe core business of China Aircraft Leasing Group Holdings Limited (CALC) progressed steadily with remarkable improvements in operating quality and efficiency. The net profit attributable to shareholders recorded a year-on-year increase. As of June 30, 2025, CALC’s fleet reached 181 aircraft, leased to 41 airlines across 22 countries and regions. Everbright Senior Healthcare has been seizing the development opportunities in China's healthcare industry. As of 30 June 2025, Everbright Senior Healthcare has 237 institutions of various types in 49 cities across the country, it managed more than 30,000 beds, with occupancy rates increasing by 1.77%. Meanwhile, Terminus continued to deepen the integration of AI technology across multiple industries, driving intelligent transformation and implementing localised AI applications and digital-intelligent solutions, while receiving multiple authoritative certifications.Seventhly, CEL Strengthened ESG Framework to Promote Sustainable DevelopmentDuring the reporting period, CEL continued to promote the construction of its ESG system. the Company maintained an "A" rating in the MSCI ESG Rating and received the "BEST ESG (S)" award from the Hong Kong Investor Relations Association (HKIRA). The Company earnestly fulfilled its role as a corporate citizen by leveraging its own capabilities, organizing and participating in 46 cultural and social welfare activities in the first half of the year, serving over ten thousand people, and upholding high standards in discharging its social responsibilities.In the first half of 2025, under the strong leadership of the Everbright Group, the guidance of the Board of Directors, and the collective efforts of all employees, the Company achieved significant improvements in operational efficiency and quality, with new drivers of growth continuing to strengthen, resulting in hard-won achievements. As China's economy continues to improve and policy support intensifies, the Chinese private equity industry will embark on a new journey of high-quality development. CEL will seize market opportunities, capitalise on the momentum, and lay a solid foundation for a strong start to the 15th Five-Year Plan. In the second half of the year, CEL will continue to adhere to the overall principle of seeking progress while maintaining stability, continue to focus on revenue growth and cost control, optimise operational management, seize opportunities in key business areas such as fundraising, investment, management, and exit, leverage the cross-border platform and the synergistic advantages of the group, cultivate long-term patient capital, and advance the "five major financial initiatives", through scientific strategic planning, professional investment teams, and rigorous risk management, and continuously create value for shareholders.China Everbright Limited, https://www.everbright.com/en [SHSE:601818][HKEX:00165][OTCPK:CEVIF][OTCPK:CEVIY] Copyright 2025 ACN Newswire via SeaPRwire.com.

佛羅里達州西棕櫚灘, 2025年8月28日 - (亞太商訊 via SeaPRwire.com) - U.S. Polo Assn.是美國馬球協會（United States Polo Association, USPA）的官方運動品牌，現已達成多年合作協議，成為棕櫚灘馬拉松的新任冠名贊助商。由 Ken Kennerly 的 K2 Sports Ventures 擁有並營運的 U.S. Polo Assn. 棕櫚灘馬拉松，將於 2025 年 12 月 13-14 日在佛羅里達州西棕櫚灘市中心舉行。美國馬球協會馬拉松這項享有盛譽的馬拉松賽事因其美麗的濱水景觀和椰林大道而聞名，吸引來自全美乃至世界各地的跑者，在寒冷的冬季感受佛羅里達的溫暖。該賽事同時也是享有盛名的波士頓馬拉松的資格賽。USPA Global 總裁兼首席執行官 J. Michael Prince 表示：“U.S. Polo Assn. 很榮幸能夠成為棕櫚灘馬拉松的冠名贊助商。這是一項標誌性的賽事，就像我們的品牌一樣，深深植根於充滿活力的棕櫚灘縣社區。儘管我們這一個受運動啟發的品牌已經在全球 190 多個國家擁有廣泛的影響力，但我們的核心與傳承正是在棕櫚灘。這裡是 USPA Global、美國馬球協會以及全球最具聲望的馬球勝地——USPA 國家馬球中心的所在地。”賽事週末活動將於 12 月 13 日（星期六）上午 7:30 舉行 5 公里和 10 公里賽，隨後在 12 月 14 日（星期日）上午 6:00 舉行主賽事，包括馬拉松、半程馬拉松以及馬拉松接力賽。目前已開放早期報名：馬拉松報名費為 130 美元，半程馬拉松為 100 美元；10 公里早期報名費為 60 美元，5 公里為 45 美元。報名請訪問 palmbeachmarathon.com。健康與健身博覽會（Health and Fitness Expo）將與選手領取參賽包同時進行，時間為 12 月 12 日（星期五）中午 12:00 至下午 6:00，以及 12 月 13 日（星期六）上午 10:00 至下午 6:00，地點在西棕櫚灘 Datura 街 104 號的 Meyer Amphitheatre。博覽會將展示最新的健康與健身產品和服務、跑步裝備，以及未來賽事相關資訊。Kennerly 表示：“我們非常高興能迎來像 U.S. Polo Assn. 這樣享譽全球的品牌成為棕櫚灘馬拉松的冠名贊助商。這對賽事的未來以及其對全球跑者的吸引力來說，都是一件極其重要的事情。棕櫚灘是全球公認的一流目的地，我們期待著賽事不僅能在本地社區持續發展，同時也能在國際舞台上不斷壯大。”U.S. Polo Assn. 品牌產品涵蓋男裝、女裝、童裝，以及配飾、行李箱、手錶、鞋履、家居用品等，並透過獨立零售店、百貨商店、U.S. Polo Assn. 品牌專賣店以及電子商務渠道，在全球 190 個國家進行銷售。Prince 補充道：“與棕櫚灘馬拉松的合作，讓我們能夠共同慶祝體育卓越、社區精神、健康與福祉，以及那份將我們在本地與全球相連的運動熱情。從馬球賽場到棕櫚灘的街道，我們從全力以赴的運動員身上汲取靈感，並期待能共享那份激情、友誼以及世界級競賽氛圍，這正是棕櫚灘馬拉松的獨特魅力所在。”本次賽事還將支持即將公布的本地慈善項目。由赫斯特（Hearst）集團旗下的 ABC 聯盟台 WPBF 25 將繼續擔任賽事官方轉播電視台，不僅會在賽前和賽後透過所有電視頻道和數位平台進行廣泛報導，還將在馬拉松比賽當天上午進行現場直播。WPBF 25 總裁兼總經理 Caroline Taplett 表示：“WPBF 25 非常高興能夠連續第二年擔任 U.S. Polo Assn. 棕櫚灘馬拉松的官方轉播電視台，這再次體現了我們致力於將這樣一項獨特而激動人心的賽事帶給社區的承諾。與我們出色的合作夥伴 Ken Kennerly 及馬拉松團隊攜手，我們將全力推動社區聯繫更加緊密，支持本地企業，並激勵來自本地、全國乃至全球的參賽者齊聚美麗的南佛羅里達，共同參與這場獨一無二的體驗。”關於 U.S. Polo Assn. U.S. Polo Assn. 為美國馬球協會（USPA）之官方品牌，該協會創立於 1890 年，是北美最大馬球俱樂部與馬球運動員聯盟。今年，U.S. Polo Assn. 與美國馬球協會（USPA）共同慶祝品牌成立 135 週年，持續從體育汲取靈感。 該品牌在全球範圍內贊助大型馬球賽事，其中包括每年在棕櫚灘 USPA 國家馬球中心（NPC）舉行的 美國馬球公開賽®（U.S. Open Polo Championship®），這是美國最頂級的馬球賽事。U.S. Polo Assn. 擁有數十億美元的全球品牌價值，並透過逾 1,100 間品牌零售店及數千個銷售據點，在全球超過 190 個國家提供男裝、女裝、童裝、配件與鞋類產品。透過與美國 ESPN、歐洲的TNT和印度 Star Sports 的歷史性協議，U.S. Polo Assn. 贊助的多項世界頂級馬球賽事首次轉播至全球數百萬體育迷，讓這項激動人心的運動登上世界舞台。據《License Global》報導，U.S. Polo Assn. 長期被評為全球頂尖體育授權品牌之一，與 NFL、PGA Tour 和 Formula 1 並列。此外，該品牌亦因於全球及數位市場的成長，獲得多項國際獎項肯定。 U.S. Polo Assn. 曾登上《富比士》、《財富》、《現代零售》和《GQ》等主流媒體，也多次出現在 Yahoo Finance 與 Bloomberg 等財經平台。關於 U.S. Polo Assn. 棕櫚灘馬拉松U.S. Polo Assn. 棕櫚灘馬拉松是一項頂級的冬季長跑賽事，每年在西棕櫚灘舉行，設有多種賽程，適合各類跑者參加，包括全程馬拉松、半程馬拉松、10 公里、5 公里以及四人馬拉松接力。賽事路線為 100% 平坦且經 USATF 認證，並具備波士頓馬拉松資格賽資格。賽道風景優美，跑者不僅能體驗充滿活力的西棕櫚灘市中心，還能沿著棕櫚樹成蔭的 Flagler Drive 前行，途經歷史街區，並欣賞到閃耀的濱水景觀。該賽事同時也支持社區和慈善事業。詳情請訪問 palmbeachmarathon.com 。聯絡資訊Stacey KovalskyU.S. Polo Assn. skovalsky@uspagl.com(954) 673-1331Gary FermanSpecialty Sports(954) 558-5203來源: U.S. Polo Assn. Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) – 商湯集團股份有限公司（「商湯集團」或「公司」，股份代號：0020）今日公佈截至2025年6月30日止半年度（「2025年上半年」）的中期業績。2025年上半年，商湯集團業績超出市場預期，總收入按年增長36%，達人民幣24億元；其中，生成式AI收入連續第三年高速增長，增幅達73%；經調整虧損淨額按年和按月均大幅收窄，按年下降50%；貿易應收回款額32億元，以96%大幅提升，達歷史新高。截至2025年上半年，集團的總現金儲備132億元。2025年上半年，商湯持續深化「1+X」戰略並取得實質性進展，完成業務動能穩健和結構優化。「1+X」以生成式AI與視覺AI作為「1」的核心業務，亦是雙引擎，而「X」代表的X創新業務板塊以孵化創新生態為核心戰略，聚焦智能駕駛、智慧醫療、家用機械人、智慧零售等四個賽道。生成式AI佔集團收入進一步提升至77%，日日新大模型多模態能力躋身世界前沿，大模型應用圍繞「生産力工具」和「互動工具」 兩大場景，快速提升滲透率和客戶忠誠度。當中生産力工具以商湯「小浣熊」産品為代表，提供金融、教育、政務三大版本，用戶數突破300萬。在互動工具領域，「日日新 V6.5」實現了文本與音視頻融合，多模態實時互動時數年內增長510%。視覺AI重啓增長曲綫，以高質量客戶策略和領先市場佔有率，實現利潤空間與現金流雙向改善。截至2025年6月底，視覺AI板塊服務國內外客戶660餘家，複購比例57%，上半年海外商機儲備與新訂單按年顯著增長。組織上，圍繞「1」和「X」進行二次聯合創業，形成專業化與多元化兼備的領導架構，針對創新業務任命獨立的聯創團隊，實現「X創新業務」在戰略重組後釋放經營活力與資本市場吸引力。商湯科技董事長兼首席執行官徐立博士表示：「在國務院發佈《關於深入實施「人工智能+」行動的意見》重要舉措的背景下，商湯緊抓落地機遇，深耕行業領域，以生成式AI與視覺AI為雙引擎，使商湯在繼續保持視覺AI龍頭地位基礎上，抓住生成式AI 所帶來的歷史性窗口，為員工、客戶和股東持續創造價值。」2025年上半年集團核心經營亮點- 整體收入按年增長36%，達到24億元人民幣，增速較往年進一步提升；經調整EBITDA與經調整淨虧損顯著改善，按年收窄幅度分別達72.5%和50%；- 應收款回款金額創歷史新高，達32億元人民幣，按年增長96%；貿易應收周轉天數同比縮短49%；- 經營活動現金流淨流出按年大幅收窄82%，現金創造能力不斷增强；總現金儲備攀升至132億元人民幣，為集團聚焦長期戰略實施提供了充裕的資金保障。關於商湯作為人工智能軟件公司，商湯科技以「堅持原創，讓AI引領人類進步」為使命，旨在持續引領人工智能前沿研究，持續打造更具拓展性更普惠的人工智能軟件平台，推動經濟、社會和人類的發展，並持續吸引及培養頂尖人才，共同塑造未來。商湯科技擁有深厚的學術積累，並長期投入於原創技術研究，不斷增强行業領先的多模態、多任務通用人工智能能力，涵蓋感知智能、决策智能、智能內容生成、自然語言處理等關鍵技術領域，同時包含AI芯片、AI傳感器及AI算力基礎設施在內的關鍵能力。此外，商湯前瞻性打造新型人工智能基礎設施——商湯AI大裝置SenseCore，打通算力、算法和平台，並在此基礎上建立「商湯日日新SenseNova」大模型及研發體系，以低成本解鎖通用人工智能任務的能力，推動高效率、低成本、規模化的AI創新和落地，進而打通商業價值閉環，解决長尾應用問題，引領人工智能進入工業化發展階段。商湯科技業務涵蓋生成式AI、視覺AI和X創新業務，相關産品與解决方案深受客戶與合作夥伴好評。商湯倡導「發展」的人工智能倫理觀，並積極參與有關數據安全、隱私保護、人工智能倫理道德和可持續人工智能的行業、國家及國際標準的制訂，與多個國內及多邊機構就人工智能的可持續及倫理發展開展了密切合作。商湯《AI可持續發展道德準則》被聯合國人工智能戰略資源指南選錄，並於2021年6月發表，是亞洲唯一獲此殊榮的人工智能公司。目前，商湯科技已於香港交易所主板掛牌上市。商湯在香港、上海、北京、深圳、成都、杭州、西安、新加坡、曼谷、吉隆坡、利雅得、阿布扎比、杜拜、首爾等地設立辦公室。另外，商湯科技在德國、泰國、印尼、菲律賓等國家均有業務。更多資訊，請瀏覽商湯科技網站、微信、微博和領英。 Copyright 2025 亞太商訊 via SeaPRwire.com.

財務摘要 (未經審核)（港幣千元）截至六月三十日止六個月2025年2024年收入122,775135,347毛利47,27748,767本公司所有者應佔溢利8,17218,510毛利率39%36%每股基本盈利 (港仙)0.581.31香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) – 中國優質葡萄酒生產商王朝酒業集團有限公司（「王朝」或「集團」）（股份代號：00828）今日公佈截至2025年6月30日止未經審核之中期業績。2025年上半年，由於集團加強沿海地區乾白酒市場的開拓力度，推出新的白葡萄酒及起泡葡萄酒產品，集團白葡萄酒產品的銷售收入保持良好勢態。但受中國宏觀經濟及消費市場波動的影響，集團產品（尤其是高端葡萄酒產品）銷量下跌，以及由於推廣及宣傳開支增加，集團2025年上半年收入較2024年同期下跌9%至約1.23億港元，本公司所有者應佔溢利較2024年同期減少56%至約8.2百萬港元，每股基本盈利約為每股0.58 港仙。期內由於產品組合優化，集團毛利率由去年同期的36%上升至39%。集團白葡萄酒產品的銷售於期內為集團的主要收益貢獻來源。紅葡萄酒與白葡萄酒產品的銷售收入分別佔集團整體收入約41%及54%。期內，紅葡萄酒產品和白葡萄酒產品的毛利率分別為38%及39%。本集團積極求新，聚焦「5+4+N產品戰略」，其中「N」代表集團推出N項需求定制，不斷開拓創新產品，以滿足中國不同類型消費群體的多元化需求。於回顧期內，本集團繼續推出新產品及進行產品升級，以更好地滿足不同葡萄酒口味及不同消費能力的消費者，旨在激發品牌活力，並鞏固王朝作為國產葡萄酒代表的品牌形象。本集團以「王朝」品牌產銷超過100種葡萄酒產品，迎合中國葡萄酒市場大眾市場分部不同消費者群的各項需求和喜好。於回顧期內，本集團推出中高端新品－王朝乙巳蛇年生肖紀念乾紅葡萄酒，與中國生肖文化相融合，引領「國潮風」，以年輕化的視覺語言呈現生肖文化，吸引潛在消費者。於本期間，本集團持續加強與酒業協會的合作，開展「龍行高校」等活動，進一步擴大品牌在年輕族群中的認知度與美譽度。基於其現有的優質產品，本集團繼續推出新產品並推進產品升級。本集團於二零二五年三月在第112屆全國糖酒商品交易會上推出天陽茶酒系列、王朝百馥VSOP白蘭地等新品，以進一步完善其產品矩陣，為消費者提供多元的消費選擇。該系列茶香葡萄酒突破傳統葡萄酒的局限，以「茶酒融合」為核心理念，憑藉獨特的釀造工藝迅速獲得市場目光。這款茶香葡萄酒以白酒為基調，融合茉莉花及普洱茶的芬芳，在傳統的氣泡酒領域中，創造出一種全新的東方韻味。在全國糖酒商品交易會期間，本集團亦舉辦品酒會，王朝天夏酒莊的新品憑藉獨特的風味和精湛的釀造工藝，贏得業界的好評。除致力於中國核心葡萄酒業務外，本集團亦將通過新設立的合資公司，拓展新的酒類飲料領域，如醬香型白酒、黃酒及特種黃酒－陳皮酒，以實現收入來源的多元化。王朝醬香型白酒產品，即「漢」、「唐」、「宋」、「明」，已於天津核心市場新推出並得到熱烈迴響，並將於下半年進一步戰略推廣至其他地區。醬香型白酒產品滿足不同消費習慣的客戶群體的需求，並為本集團業務作出貢獻。未來，醬香型白酒產業的發展及擴張及客戶群體水平的持久提升，必將有效推動王朝葡萄酒及相關產品銷售的增長，從而提升我們的行業影響力及品牌知名度。對於黃酒項目，經規劃後，正於二零二五年下半年在江蘇建設一座儲罐容量為3,000噸黃酒及特種黃酒－陳皮酒的生產廠房。於建設工程竣工後，本集團將能夠生產特種黃酒－東台陳皮酒，讓本集團可有效擴展產品品類，把握中國黃酒行業的發展機遇，實現酒業高質量發展的重大戰略舉措。電商銷售方面，於回顧期內，本集團的電商團隊於傳統電商平台全面運營在線商店銷售產品，例如京東商城、天貓商城及拼多多，以及通過興趣電商平台（包括小紅書app、快手app及抖音app）全面創新品牌、品類、業務體系、流程和模式。本集團的自主品牌傳播使其可繼續獲得主流消費群體和圈子的關注，並提高本集團面向年輕消費者的產品的有效市場滲透率。同時，電商團隊積極培養電商直播人才，以進一步擴大其銷售渠道及建立新客戶群。此外，於回顧期內，本集團在大型葡萄酒品鑒大賽中屢獲殊榮。在多個獎項中，「王朝錦邑桶藏12年XO白蘭地」榮獲二零二五年國際葡萄酒與烈酒大賽（「IWSC」）中的銀獎。該比賽被視為葡萄酒和烈酒質量的國際評價標準。王朝百馥VSOP白蘭地、金王朝馬瑟蘭乾紅葡萄酒以及天陽茶酒系列亦於中國酒業協會舉辦的「二零二四年青酌獎」各類別評選中獲獎。「王朝夢園白葡萄酒」亦以其卓越的酒質榮獲二零二五年春季FIWA法國國際葡萄酒大獎賽中國區金獎。此外，「王朝傳承系列－乾紅葡萄酒」於同一比賽中榮獲金獎。該等葡萄酒因其酒香優雅、酒體順滑和口感圓潤從眾多參賽作品中脫穎而出，並在比賽中獲得獎項，向國家及世界展示了王朝葡萄酒的魅力和實力。王朝主席萬守朋先生總結︰「展望二零二五年下半年，本集團將繼續聚焦市場和消費者需求，並通過技術創新提升產品質量。同時，本集團將繼續創新營銷策略，激發品牌活力，進一步擴大王朝產品的市場份額，加強王朝品牌作為國產葡萄酒代表的形象，並為中國葡萄酒行業樹立標桿，將王朝美酒風尚帶給更多的中國消費者。本集團將繼續通過產品品類及消費場景的創新，以及跨行業合作，積極開拓新的營銷前景，以提升銷量，藉此支持國家擴大內需及釋放消費增長潛力的工作。」關於王朝酒業集團有限公司王朝酒業集團有限公司於2005年1月26日在香港聯合交易所有限公司主板上市，股份代號00828。成立於1980年，王朝爲中國優質葡萄酒生産商，主要生産及銷售「王朝」商標的葡萄酒産品，是中國第一家中外合資的釀酒企業，主要股東包括天津食品集團有限公司及法國葡萄酒巨頭人頭馬集團。集團產銷葡萄酒產品系列超過100種，及引入進口葡萄酒產品，為國內各消費層提供高質素及物超所值的葡萄酒。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 8月27日，澳優乳業股份有限公司（股份代號：1717.HK，以下簡稱"澳優"或"公司"）發布2025年上半年業績公告。公告顯示：2025年1-6月，澳優實現營業收入約人民幣38.87億元，同比增長5.6%；實現EBITDA（息稅折舊及攤銷前利潤）約人民幣3.98億元，同比增長29.7%；歸屬于母公司權益持有人應占利潤約人民幣1.81億元，同比增長24.1%，實現營收利潤持續韌性雙增長。 公告表示，2025年上半年，面對複雜多變的全球經濟形勢及競爭加劇的中國嬰配粉市場環境，澳優穩步推進"奶粉+營養品"全家營養戰略，進一步打造産品力、品牌力、渠道力、數智力及組織力，在消費者的信任、社會各界的支持和全體澳優人的共同努力下，營收、利潤繼續保持雙增長趨勢，以堅韌不拔的毅力和穩健扎實的步伐邁向高質量發展新階段。分版塊看，澳優自有品牌奶粉業務實現整體營收約人民幣28.26億元。其中，羊奶粉業務實現收入18.65億元，同比增長3.1%，"領頭羊"地位持續穩固，尼爾森IQ數據顯示截至6月底公司羊奶粉市場占有率同比提升2.8個百分點至30.4%；在2024年中國進口嬰幼童羊奶粉市場銷售量份額及銷售額份額均高達84%，已連續7年在中國進口嬰幼童羊奶粉市場份額超6成。【1】與此同時,弗若斯特沙利文經市場研究確認：2024年佳貝艾特羊奶粉銷量與銷售額全球第一。【2】牛奶粉業務實現收入約人民幣9.61億元。營養品業務實現收入同比增長7.0%，幷成功拓展至海外市場。分區域看，2024年羊奶粉中國業務實現收入約人民幣13.81億元；羊奶粉國際業務實現收入約人民幣4.83億元，同比大幅增長65.7%，國際業務多點開花，實現爆發式增長，在公司自有品牌配方羊奶粉業務總收入的占比進一步提升至25.9%。公告顯示，中東地區在2025上半年繼續保持澳優海外最大銷售市場的地位；北美地區收入同比提升逾138.7%，成為澳優海外市場第二大營收來源，獨聯體地區收入同比增長33.8%。澳優在公告中表示，羊奶粉業務海外市場在過去兩年保持高雙位數複合增長率的基礎上，于上半年再攀高峰，實現同比增長65.7%；營養品業務戰略布局全面起勢，成為驅動公司發展的重要動力。數據來源：【1】尼爾森IQ進口嬰幼童羊奶粉零售追踪數據；時間段：2018年-2024年，連續7個年度；渠道範圍：上海、江蘇、浙江、安徽、河南、廣東、湖南、湖北、福建、江西、北京、天津、黑龍江、吉林、遼寧、山東、山西、河北、陝西、四川、重慶、貴州、雲南、廣西的城市母嬰渠道。【2】弗若斯特沙利文Frost & Sullivan《全球羊奶粉市場獨立研究報告》（2025年4月）。基于對全球羊奶粉市場的研究，對2024年全球範圍內主要羊奶粉品牌的銷量以及銷售額進行研究分析後做出的確認，調研數據覆蓋2024年1月至12月。 Copyright 2025 亞太商訊 via SeaPRwire.com.

- 华堂宁(R)銷量同比增長108%，淨銷售額同比增長112%。醫保覆蓋持續擴大，二級和三級醫院處方量顯著增加，全面自主商業化成效顯著。- 與拜耳終止獨家推廣服務協議後，確認一次性遞延收入人民幣12.435億元，實現上半年盈利11.839億元，公司在業績期內首次實現盈利。- 在中國開展涉及80個中心和2000名2型糖尿病患者的真實世界研究，進一步證明多格列艾汀的廣泛適用性和安全性。- 多格列艾汀75mg（商品名：MYHOMSIS(R)，華領片TM）在香港遞交註冊申請，加速佈局大中華區及東南亞市場。- 毛利率顯著提升，生產規模與運營效率持續優化。上海，2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 華領醫藥（"公司"，香港聯交所股份代號：2552）宣佈公司及其附屬公司截至2025年6月30日止六個月（"報告期"）未經審核的綜合業績，以及公司上半年業務進展與未來展望。報告期內，公司核心產品华堂宁(R)（多格列艾汀片）商業化加速，自主運營能力顯著提升，研發進展順利推進，財務表現實現突破性成長，為長期可持續發展奠定了堅實基礎。華領醫藥創始人兼首席執行官陳力博士表示："2025 年上半年是華領醫藥轉型發展的關鍵階段。全面接管华堂宁(R)商業化後，公司憑藉自主搭建的銷售團隊，實現了銷量與收入的翻倍增長，印證了新的商業模式的有效性。我們還在中國香港遞交了新藥上市申請，為多格列艾汀從中國走向東南亞乃至全球市場奠定了基礎。同時，多格列艾汀在真實世界研究中持續展現出廣泛的治療潛力，也在基礎研究中發現了糖尿病緩解、認知改善、血脂改善和增肌等方面的新證據，進一步鞏固了華領醫藥在GKA研發和治療領域的全球領先地位。未來，華領醫藥將繼續深耕糖尿病和整個代謝疾病領域，通過創新研發與市場拓展的雙輪驅動，讓中國原創新藥惠及更多全球患者。"業務亮點與運營進展商業化轉型成效顯著，銷售與利潤雙增長- 2025年1月1日起，公司終止與拜耳的獨家推廣服務協議，全面接管华堂宁(R)在中國的商業化運營。報告期內，在與2024年同期的單價保持一致的情況下，华堂宁(R)銷量達176.4萬盒，同比增長108%；淨銷售額達2.174億元，同比增長112%。憑藉強勁的商業執行力和不斷提升的運營效率，公司邁向盈利。華領醫藥已順利過渡到全面自主商業化階段，也印證了日益增長的市場需求和自主銷售團隊的高效執行力。- 2024年被納入中國國家醫保藥品目錄(NRDL)後，2025年华堂宁(R)繼續受益於廣泛的醫保覆蓋，二級和三級醫院的處方量顯著增加，有助於提高患者的可及性和長期使用率。- 由於生產規模擴大和成本效率的提升，公司毛利率提升至54.2%，高於去年同期的46.5%。- 在銷售額同比增長112%的情況下，報告期內公司銷售費用為6420萬元，與去年同期相比僅增長5%，報告期內銷售費用約占總收入的29.5%，顯著低於去年同期的59.5%。這是因為，2025年上半年銷售費用構成與2024年同期相比發生了顯著變化：由公司在中國承擔华堂宁(R)的獨家商業化責任而直接產生銷售費用，而無需再向原商業化合作夥伴支付推廣費用。這反映出公司顯著的盈利向好趨勢，也表明了公司的業務戰略，即通過控制與华堂宁(R)商業化直接相關的銷售費用，以及最大限度地提高生產效率，來優化盈利能力。- 與拜耳終止獨家推廣服務協議後，公司確認一次性遞延收入12.435億元，向自主驅動增長轉型。華領醫藥首次實現半年稅前利潤11.839億元，這是華領醫藥邁向可持續盈利的關鍵里程碑。- 截至2025年6月30日，現金餘額為10.228億元，為公司未來的研發和商業化舉措奠定了堅實基礎。臨床研究持續深入，新證據支撐治療潛力- 公司正在推進多項上市後研究，以評估多格列艾汀在不同患者群體中的長期安全性和有效性，包括單藥治療以及與其它已經獲批的熱門降糖藥，如GLP-1受體激動劑、胰島素、DPP-4抑制劑和SGLT-2抑制劑的聯合用藥。這些研究正在為血糖控制、認知改善和糖尿病緩解潛力等提供新的臨床依據。- 公司正在開展多格列艾汀上市後真實世界研究（BLOOM），在全國80家中心納入2000例2型糖尿病患者，目前已完成1000余例患者的1年隨訪。在真實世界環境中，BLOOM研究進一步證明了多格列艾汀的廣泛適用性和安全性。在臨床用藥中，接受多格列艾汀治療的患者往往存在多種合並症，包括各種心血管和腎臟疾病等，並且正在接受多種伴隨藥物治療。除二甲雙胍外，超過60%的患者在使用多格列艾汀的同時，還聯合使用了SGLT-2抑制劑、胰島素、GLP-1受體激動劑或DPP-4抑制劑等其它降糖藥。無論是單藥治療還是聯合用藥，多格列艾汀普遍表現出良好的耐受性，安全性特徵也與先前的臨床研究資料保持一致。- 在2025年美國糖尿病協會（ADA）科學年會上，公司公佈了多格列艾汀的新研究資料，進一步闡明其作為疾病修飾療法的作用機制，關於多格列艾汀作為GKA藥物的新作用機制的相關成果已發表於《糖尿病》（Diabetes）雜誌上。研發管線與未來展望- 公司已在中國香港提交多格列艾汀75mg（商品名：華領片TM，MYHOMSIS(R)）的註冊申請，旨在擴大在大中華區和東南亞的業務版圖。- 公司正在通過開發二甲雙胍和多格列艾汀的固定複方製劑拓展產品管線，用於服用高劑量二甲雙胍（>每日1500mg）仍無法控制血糖的患者，此前的DAWN臨床研究顯示，多格列艾汀聯合二甲雙胍用藥可使患者的糖化血紅蛋白（HbA1c）降低超過1%，餐後血糖降低超過5mmol/L，低血糖發生率僅為0.8%。該血糖控制水準表明，多格列艾汀-二甲雙胍固定劑量複方製劑作為口服降糖藥具有強大的潛在需求。2025年8月，公司已完成IND前資料提交，預計於2026 年初啟動生物等效性（BE）研究。- 通過收集真實世界證據以及在動物模型中開展概念驗證研究，公司正在推進多格列艾汀與GLP-1受體激動劑、DPP-4製劑和SGLT-2抑制劑的聯合用藥。多格列艾汀與這些藥物之間的協同作用有望將其適應症擴展到肥胖症、代謝相關脂肪性肝炎（MASH）等其它代謝紊亂疾病領域。- 公司將繼續加強與國際領先的研究機構的合作。由華領醫藥支持的一項研究者發起的I 期臨床研究正在賓夕法尼亞大學進行，旨在評估多格列艾汀在囊性纖維化相關糖尿病（CFRD）患者中的療效和安全性，該試驗已獲得美國食品藥品監督管理局（FDA）的批准。- 公司將繼續致力於開發糖尿病預防、代謝紊亂相關神經退行性疾病領域的治療機遇，最終找到一種新的方法來延長人類的健康壽命。- 公司將繼續投資於數字技術平台，以在各個職能部門之間創造協同效應，並利用人工智慧技術提升品牌機遇。- 公司將繼續自主推進多格列艾汀和第二代GKA的研發，並與學術和戰略合作夥伴共同開展相關工作。公司正在推進多格列艾汀在香港的註冊，並繼續在東南亞和"一帶一路"國家尋求合作夥伴。基於美國I期單劑量遞增研究的初步成功，公司計劃於2025年底或2026年初啟動多劑量遞增I期研究，從而繼續推動第二代GKA在全球市場的業務發展。財務摘要截至2025年6月30日- 公司銀行結餘及現金約人民幣10.228億元- 總營收約2.174 億元，同比增長112%，华堂宁(R)銷量達176.4萬盒，同比增長108%- 毛利約1.178億元，同比增長147%，毛利率約54.2%，同比增長7.7個百分點- 其他收入約12.546億元，其中拜耳一次性遞延收入為12.435億元- 總開支約1.871億元，其中研發開支約6580萬元- 稅前利潤約11.839億元，同比增長932%前瞻性聲明本文包含有關華領醫藥以及產品未來預期、計劃和前景的陳述。該等前瞻性陳述僅與本文作出該陳述當日的事件或資料有關，可能因未來發展而出現變動。除法律規定外，於作出前瞻性陳述當日之後，無論是否出現新資料、未來事件或其他情況，我們並無責任更新或公開修改任何前瞻性陳述及預料之外的事件。請仔細閱讀本文並理解，由於各種風險、不確定性或其他法定要求我們的實際未來業績或表現可能與預期有重大差異。關於華領華領醫藥（"本公司"）是一家總部位於中國上海的創新藥物研發和商業化公司，在美國、中國香港設立了公司。華領醫藥專注於未被滿足的醫療需求，為全球患者開發全新療法。華領醫藥匯聚全球醫藥行業高素質人才，融合全球創新技術，依託全球優勢資源，研究開發突破性的技術和產品，引領全球糖尿病醫療創新。公司核心產品华堂宁(R)（多格列艾汀片）以葡萄糖感測器葡萄糖激酶為靶點，提升2型糖尿病患者的葡萄糖敏感性，改善患者血糖穩態失調。2022年9月30日，华堂宁(R)已獲得中國國家藥品監督管理局（NMPA）的上市批准，用於單獨用藥或者與二甲雙胍聯合用藥，治療成人2型糖尿病。對於腎功能不全患者，無需調整劑量，是一款可用於腎功能損傷的2型糖尿病患者的口服降糖藥物。詳情垂詢華領醫藥網址：www.huamedicine.com投資者電郵：ir@huamedicine.com媒體電郵：pr@huamedicine.com新聞免責聲明本材料，如為上下文論述的準確性和完整性，提及在中國上市的產品相關資訊的，特別是標識或要求，應遵循中國監管機構批准的相關檔。另外，相關資訊不應被解讀為對任何藥物或者診療方案的推薦或者宣傳，亦不應替代任何醫療衛生專業人士的醫療建議，涉及醫療的相關事宜務必諮詢醫療衛生專業人士。 Copyright 2025 亞太商訊 via SeaPRwire.com.

香港，2025年8月28日 - (亞太商訊 via SeaPRwire.com) - 2025年8月，北京--首程控股有限公司（0697.HK，以下簡稱「首程控股」）、北京首程機器人科技產業有限公司（以下簡稱「首程機器人」）、阿爾特汽車技術股份有限公司（300825.SZ，以下簡稱「阿爾特」）、北京阿爾瑞特智能機器人科技有限公司（以下簡稱「阿爾瑞特」）正式簽署戰略合作框架協議。四方將充分發揮各自優勢，圍繞機器人產業的技術創新、應用落地、產業鏈協同與人才培養，展開全方位合作，推動「機器人+汽車」應用新業態加速發展。一、產業背景：機器人進入應用落地加速期當前，全球機器人產業正處於高速發展階段，國家戰略和政策密集出台。8月26日，國務院正式發佈《國務院關於深入實施「人工智能+」行動的意見》（國發〔2025〕11號），明確提出要推動人工智能與經濟社會各行業各領域的廣泛深度融合，加快形成人機協同、跨界融合、共創分享的智慧經濟和智慧社會新形態。在這一國家戰略指引下，機器人產業正從「技術突破」邁向「應用落地」。汽車與機器人作為兩個高度契合的產業，正逐漸呈現跨界融合趨勢。此次首程控股與阿爾特集團的合作，將在政策東風與市場需求的雙重驅動下，為機器人在研發、製造、交通和出行服務等關鍵環節的應用注入新動能。阿爾特是中國汽車設計領域的領軍企業，也是A股市場唯一的獨立汽車設計上市公司，具備整車研發設計與核心零部件製造的全流程服務能力，並踐行「技術+供應鏈」的國際化戰略。據公開資訊，公司累計服務超過80家客戶，參與開發近500款車型，客戶涵蓋一汽、東風、北汽、吉利、新勢力品牌與合資企業等主機廠類型。這意味著阿爾特在汽車產業鏈中擁有深厚的主機廠資源與交付能力。與此同時，阿爾特通過控股子公司--北京阿爾瑞特智能機器人科技有限公司，已正式開闢機器人新賽道。阿爾瑞特致力於打造一體化研發設計與仿真訓練平台，能夠為多場景機器人開發提供從仿真、測試到優化的全流程支撐；目前已啟動輪式機器人、水下機器人、鑽井機器人和寵物洗護機器人等多個研發項目，體現了其跨場景研發和產業協同的潛力。阿爾瑞特的加入，使本次合作不僅侷限於傳統汽車設計層面的協作，更在機器人研發、仿真與汽車產業化融合方面提供了重要支撐。與阿爾特及阿爾瑞特的合作，將幫助首程把機器人技術深度嵌入汽車產業鏈的核心環節，如整車製造、智能裝配與產線測試，使機器人真正進入產線、加速產業應用。這一戰略合作不只是一種技術對接，更是借助阿爾特在主機廠客戶群體中的資源網絡，將機器人場景從「隔壁展示」一步推向「生產車間」，連接研發驗證與規模化交付的關鍵路徑。二、合作重點：研發突破與應用落地並舉在國務院「人工智能+」行動政策引領下，四方將立足「技術研發-產業應用-生態共建」全鏈條，協同推進產業創新，重點在以下方向展開合作，助力機器人與汽車深度融合：（一）技術創新與聯合研發四方將聯合建設機器人一體化研發與仿真平台，借鑒汽車行業的完整研發體系，重點在運動控制、結構優化、車規級零部件和規模化製造等關鍵環節實現突破。同時，依託 NVIDIA Isaac/Omniverse 技術，共同打造一體化仿真訓練平台，不僅支援機器人在汽車研發、製造和測試中的應用模擬，還可開展智能駕駛車輛與物流機器人協同作業等跨場景模擬。雙方還將建立數據與成果共享機制：首程控股提供來自交通、出行等運營環節的數據資源，阿爾特輸出汽車工程和機器人研發經驗，形成從仿真-研發-驗證-產線應用的完整閉環。（二）優先採購與協同機制在研發設計、仿真訓練、整機和零部件供應等環節，四方將實行優先採購機制，在同等條件下優先選擇協議方為合作夥伴。首程控股與首程機器人重點提供產品推廣、代理及配套服務；阿爾特與阿爾瑞特聚焦於技術研發、工程化驗證和客製化整機開發。各方將協同推進機器人本體二次開發，確保機器人產品在汽車生產線、智能裝配和產線檢測等場景下實現最佳適配。通過分工協作，形成產品供給-技術創新-應用反饋的互補格局，加快成果轉化，提升商業化效率。（三）人才培養依託首程、阿爾特及其合作夥伴的科研與產業平台，四方將聯合開展技術攻關、仿真訓練與應用試點，為科研人員和工程師提供跨行業、跨場景的實踐環境。同時，定期舉辦技術研討會和產業論壇，邀請行業專家和上下游企業參與，建立聯合人才培養機制，打造一批兼具汽車工程背景與機器人產業化實踐經驗的青年科研人才，夯實長期發展的人才基礎。（四）拓寬發展空間四方將深度對接國家「人工智能+」與機器人產業發展戰略，重點推動「機器人+汽車」在研發、製造、測試和出行服務環節的規模化應用。在此基礎上，合作還將逐步延展至智慧交通、智能製造、醫療健康、教育、公共服務等更廣闊的領域，涵蓋機器人及核心零部件的設計、研發、生產、測試和商業化服務。同時，結合資本與產業的聯動，推動產業鏈上下游協同升級，最終形成從研發驗證到規模化應用的全鏈條閉環，打造具有示範效應的「機器人+汽車」應用矩陣，實現互利共贏和長期價值創造。三、戰略意義：打造機器人應用新標杆機器人產業的最大價值在於應用落地，而「機器人+汽車」正是最具潛力和爆發力的應用方向之一。從整車研發到智能製造，從交通調度到智慧出行，機器人將在汽車全產業鏈環節展現巨大價值。首程控股憑藉資本平台、生態資源與產業基金優勢，已投資宇樹科技、銀河通用、松延動力、星海圖、加速進化等國內頭部企業，具備前沿技術的整合能力；首程機器人則與上百家上下游優質企業建立合作，成為國內鏈接資源最全面的平台之一。阿爾特與阿爾瑞特則將汽車領域成熟的工程體系遷移至機器人研發與產業化。雙方優勢疊加，構建起「研發-迭代-應用-規模化」的完整路徑。此次攜手阿爾特，將進一步把首程的場景資源與產業生態，與阿爾特在整車研發、工程化能力與產業化經驗深度結合。未來1-2年，合作將聚焦「機器人+汽車」的深度融合，率先在汽車研發、生產製造、智慧交通與出行服務等環節實現規模化應用示範，推動機器人從實驗室走向產業化、規模化，加速形成具備示範效應的「機器人+汽車」應用矩陣。與此同時，合作也將放眼國際市場，推動中國方案走向全球，培育新質生產力，為股東創造長期價值。Posted by All Way Success Company Limited for Shoucheng Holdings www.shouchengholdings.com [HKSE:0697, FRA:SHVA, OTCPK:SHNHF] Copyright 2025 亞太商訊 via SeaPRwire.com.